U.S. patent application number 14/881428 was filed with the patent office on 2016-01-28 for antibodies against amyloid-beta peptide.
This patent application is currently assigned to Glaxo Group Limited. The applicant listed for this patent is GLAXO GROUP LIMITED. Invention is credited to Stephen Anthony BURBIDGE, Jonathan Henry Ellis, Susannah K Ford, Volker Germaschewski, Umesh Kumar, Karen Louise Philpott, Peter Ernest Soden.
Application Number | 20160024197 14/881428 |
Document ID | / |
Family ID | 38284050 |
Filed Date | 2016-01-28 |
United States Patent
Application |
20160024197 |
Kind Code |
A1 |
BURBIDGE; Stephen Anthony ;
et al. |
January 28, 2016 |
ANTIBODIES AGAINST AMYLOID-BETA PEPTIDE
Abstract
Antibodies that bind human .beta.-amyloid peptide, methods of
treating diseases or disorders characterised by elevated
.beta.-amyloid levels or .beta.-amyloid deposits with said
antibodies, pharmaceutical compositions comprising said antibodies
and methods of manufacture.
Inventors: |
BURBIDGE; Stephen Anthony;
(Harlow, GB) ; Kumar; Umesh; (Harlow, GB) ;
Philpott; Karen Louise; (Harlow, GB) ; Soden; Peter
Ernest; (Harlow, GB) ; Ellis; Jonathan Henry;
(Stevenage, GB) ; Ford; Susannah K; (Stevenage,
GB) ; Germaschewski; Volker; (Stevenage, GB) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
GLAXO GROUP LIMITED |
Brentford |
|
GB |
|
|
Assignee: |
Glaxo Group Limited
|
Family ID: |
38284050 |
Appl. No.: |
14/881428 |
Filed: |
October 13, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13491810 |
Jun 8, 2012 |
9193784 |
|
|
14881428 |
|
|
|
|
12294438 |
Sep 25, 2008 |
8227576 |
|
|
PCT/EP2007/052928 |
Mar 27, 2007 |
|
|
|
13491810 |
|
|
|
|
60787588 |
Mar 30, 2006 |
|
|
|
Current U.S.
Class: |
424/133.1 ;
424/139.1 |
Current CPC
Class: |
C07K 2317/52 20130101;
C07K 2317/94 20130101; C07K 16/18 20130101; C07K 2317/24 20130101;
A61P 25/28 20180101; C07K 2317/71 20130101; A61K 2039/505 20130101;
C07K 2317/34 20130101; C07K 2317/92 20130101; A61P 25/00
20180101 |
International
Class: |
C07K 16/18 20060101
C07K016/18 |
Claims
1. A method of treating Alzheimer's disease in a human patient
comprising administering to the patient an effective amount of an
isolated antibody or antigen binding fragment thereof which binds
.beta.-amyloid peptide and which comprises the following CDRs:
TABLE-US-00028 CDRH1: (SEQ ID No: 1) DNGMA CDRH2: (SEQ ID No: 2)
FISNLAYSIDYADTVTG CDRH3: (SEQ ID No: 3) GTWFAY
within a human heavy chain variable region originating from the VH3
gene family and: TABLE-US-00029 CDRL1: (SEQ ID No: 4)
RVSQSLLHSNGYTYLH CDRL2: (SEQ ID No: 5) KVSNRFS CDRL3: (SEQ ID No:
6) SQTRHVPYT
within a human light chain variable region originating from the
amino acid sequence disclosed in GenPept entry CAA51135 (SEQ ID
No:24).
2. The method of claim 1 wherein the isolated antibody has the
human heavy chain variable region which originates from a V gene
selected from the group consisting of: VH3-48, VH3-21, VH3-11,
VH3-7, VH3-13, VH3-74, VH3-64, VH3-23, VH3-38, VH3-53, VH3-66,
VH3-20, VH3-9 and VH3-43.
3. The method of claim 2 wherein the isolated antibody has a human
acceptor heavy chain framework of M99675 (SEQ ID No:21) together
with a framework 4.
4. The method of claim 3 wherein the isolated antibody has the
framework 4 sequence encoded by the human JH4 minigene (Kabat):
TABLE-US-00030 (SEQ ID No: 23) YFDYWGQGTLVTVSS
of which the initial four residues which fall within the CDR3
region is replaced by the incoming CDR from a donor antibody.
5. The method of claim 4 wherein the isolated antibody has a human
acceptor heavy chain framework of M99675 together with JH4
containing one to four amino acid residue substitutions selected
from positions 24, 48, 93 and/or 94 (Kabat numbering).
6. The method of claim 5 wherein the isolated antibody has a human
acceptor heavy chain framework which comprises the following
residues: TABLE-US-00031 Position Residue (i) 93 V 94 S or (ii) 24
V 93 V 94 S or (iii) 48 I 93 V 94 S
7. The method of claim 1 wherein the isolated antibody binds
.beta.-amyloid peptide comprising a V.sub.H chain having the
sequence set forth in SEQ ID No:26 and a V.sub.L domain having the
sequence set forth in SEQ ID No:32.
8. A method of treating Alzheimer's disease in a human patient
comprising administering to the patient an effective amount of an
isolated antibody or antigen binding fragment thereof which binds
.beta.-amyloid peptide and which comprises a V.sub.H chain having
the sequence set forth in SEQ ID No: 28 and a V.sub.L domain having
the sequence set forth in SEQ ID No:32.
9. The method of claim 1 wherein the isolated antibody or antigen
binding fragment thereof binds .beta.-amyloid peptide 1-12 (SEQ ID
No:15) with equilibrium constant KD less than 100 pM and has an
equilibrium constant KD for binding to b-amyloid peptide 2-13 (SEQ
ID No:44) which is 1000-fold greater than that for peptide 1-12
(SEQ ID No:15), both determinations being made in a surface plasmon
resonance assay utilising peptide captured on streptavidin
chip.
10. The method of claim 1 wherein the isolated antibody or antigen
binding fragment thereof binds .beta.-amyloid peptide 1-40 with
equilibrium constant KD less than 10 nM and has an equilibrium
constant KD for binding to b-amyloid peptide 2-13 (SEQ ID No:44)
which is 1000-fold greater than that for peptide 1-12 (SEQ ID
No:15), both determinations being made in the surface plasmon
resonance assay described in Method B of the Examples.
11. The method of claim 1 wherein the isolated antibody according
claim to 1 is of IgG1 isotype.
12. The method of claim 1 wherein the isolated antibody essentially
lacks the functions of an activation of complement by the classical
pathway; and b) mediating antibody-dependent cellular
cytotoxicity.
13. The method of claim 13 wherein the isolated antibody in which
residues 235 and 237 have been mutated to alanine.
14. A method of treating Alzheimer's disease in a human patient
comprising administering to the patient an effective amount of an
isolated antibody comprising a heavy chain having the sequence set
forth in SEQ ID No:34, 36 or 38 and a light chain having the
sequence set forth in SEQ ID No:40.
15. A method of claim 14 in which the antibody comprises a V.sub.H
chain having the sequence set forth in SEQ ID No:36 and a V.sub.L
domain having the sequence set forth in SEQ ID No:40.
16. The method of claim 1 wherein the isolated antibody or a
fragment thereof binds .beta.-amyloid peptide comprising a V.sub.H
domain having the sequence: SEQ ID No:17 and a V.sub.L domain
having the sequence: SEQ ID No:19.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to antibodies that bind
.beta.-amyloid peptide and in particular human .beta.-amyloid
peptide. The present invention also concerns methods of treating
diseases or disorders characterised by elevated .beta.-amyloid
levels or .beta.-amyloid deposits, particularly Alzheimer's
disease, with said antibodies, pharmaceutical compositions
comprising said antibodies and methods of manufacture. Other
aspects of the present invention will be apparent from the
description below.
RELATED APPLICATIONS
[0002] This application is a continuation of U.S. application Ser.
No. 12/294,438, filed Sep. 25, 2008 which claims benefit to
International Application No. PCT/EP2007/052928, filed Mar. 27,
2007, which claims benefit to U.S. Provisional Application
60/787,588 filed Mar. 30, 2006. The entire teachings of the above
applications are incorporated herein by reference.
BACKGROUND OF THE INVENTION
[0003] Alzheimer's disease (AD) is the most common cause of
age-related cognitive decline, affecting greater than 12 million
individuals worldwide (Citron M (2002) Nat. Neurosci 5, Suppl
1055-1057). The earliest stages of the disease are characterized by
a progressive loss of memory with associated cognitive decline and
language and behavioural deficits. In the later stages of the
disease, patients develop global amnesia and have greatly reduced
motor function. Death typically occurs 9 years following diagnosis
and is often associated with other conditions, typically pneumonia
(Davis K. L. and Samules S. C. (1998) in Pharmacological Management
of Neurological and Psychiatric Disorders eds Enna S. J. and Coyle
J. T. (McGraw-Hill, New York pp 267-316)). Current therapies
represent symptomatic approaches, focussing on alleviating the
cognitive impairment and ameliorating the behavioural symptoms
associated with the progressing disease aetiology. In practice
these treatments provide only a short lived cognitive benefit with
the level of cognitive impairment reported only to last up to 2
years. The potential for a disease-modifying therapy that slows and
possibly halts the progression of the disease is enormous. Such
approaches would provide radical and sustained improvements to the
quality of life of patients and importantly their carers as well as
reducing the huge overall healthcare costs of this disease.
[0004] Clinical diagnosis of Alzheimer's disease is based upon a
combination of physical and mental tests which lead to a diagnosis
of possible or probable Alzheimer's disease. At post mortem the
disease is confirmed by well characterised neurological hallmarks
in the brain, which include the deposition of A.beta. in
parenchymal plaques and cerebral vessels, intraneuronal formation
of neurofibrillary tangles, synaptic loss and loss of neuronal
subpopulations in specific brain regions (Terry, R D (1991) J
Neural Trans Suppl 53: 141-145).
[0005] A plethora of genetic, histological and functional evidence
suggests that the .beta.-amyloid peptide (A.beta.) is key to the
progression of Alzheimer's disease (Selkoe, D. J. (2001)
Physiological Reviews 81: 741-766).
[0006] A.beta. is known to be produced through the cleavage of the
beta amyloid precursor protein (also known as APP) by an aspartyl
protease enzyme known as BACE1 (also known as .beta.-secretase,
Asp2 or Memapsin-2) (De Strooper, B. and Konig, G. (1999) Nature
402: 471-472). In addition to the parenchymal and vascular
deposition, soluble oligomeric forms of A.beta. have been
postulated to contribute to the onset of AD and they may affect
neuronal function initially by impairing synaptic function (Lambert
et. al. (1998) Proceedings of the National Academy of Science,
U.S.A. 95: 6448-6453). Although insoluble amyloid plaques are found
early in AD and in MCI, the levels of soluble A.beta. aggregates
(referred to as oligomers or A.beta.-derived diffusible ligands
(ADDLs) are also increased in these individuals, and soluble
A.beta. levels correlate better with neurofibrillary degeneration,
and the loss of synaptic markers than do amyloid plaques (Naslund
et. al. (2000) J Am Med Assoc 283: 1571-1577, Younkin, S. (2001)
Nat. Med. 1: 8-19). The highly amyloidogenic A.beta.42 and
aminoterminally truncated forms A.beta.x-42 are the predominant
species of A.beta. found in both diffuse and senile plaques
(Iwatsubo, T (1994) Neuron. 13:45-53, Gravina, S A (1995) J. Biol.
Chem. 270:7013-7016) The relative levels of A.beta.42 appear to be
the key regulator of A.beta. aggregation into amyloid plaques,
indeed A.beta.42 has been shown to aggregate more readily that
other A.beta. forms in vitro (Jarrett, J T (1993) Biochemistry.
32:4693-4697) and as such A.beta.42 has been implicated as the
initiating molecule in the pathogenesis of AD (Younkin S G, (1998)
J. Physiol. (Paris). 92:289-292). Although A.beta.42 is a minor
product of APP metabolism, small shifts in it's production are
associated with large effects on A.beta. deposition therefore it
has been postulated that reduction of A.beta.42 alone may be an
effective way of treating AD (Younkin S G, (1998) J. Physiol.
(Paris). 92:289-292) In support of this, mutations in the amyloid
precursor protein (APP) and presenilin genes have been reported to
predominantly increase the relative levels of A.beta.42 and
therefore shortening the time to onset of Alzheimer's disease (AD)
(Selkoe D. J., Podlisny M. B. (2002) Annu. Rev. Genomics Hum.
Gemet. 3:67-99). It should be noted however, that the rate of
deposition is also dependant on catabolism and A.beta.
clearance.
[0007] Animal models of amyloid deposition have been generated by
overexpressing mutant human transgenes in mice. Mice overexpressing
single human APP transgenes typically develop cerebral plaque-like
.beta.-amyloid deposits from 12 months of age (Games D. et al.,
(1995) Nature 373: 523-527; Hsiao K. et al., (1996) Science 274:
99-102)), while mice carrying both mutant human APP and
presenilin-1 (PS-1) transgenes typically develop cerebral
plaque-like .beta.-amyloid deposits as early as 2 months of age
(Kurt M. A. et al., (2001) Exp. Neurol. 171: 59-71; McGowan E. et
al., (1999) Neurolbiol. Dis. 6: 231-244.
[0008] It has become increasingly apparent that the transport of
exogenous A.beta. between the central nervous system (CNS) and
plasma plays a role in the regulation of brain amyloid levels
(Shibata, et al (2000) J Clin Invest 106: 1489-1499), with CSF
A.beta. being rapidly transported from CSF to plasma. Therefore
active vaccination with A.beta. peptides or passive administration
of specific A.beta. antibodies rapidly binds peripheral A.beta.
altering the dynamic equilibrium between the plasma, CSF and
ultimately the CNS. Indeed there are now a plethora of studies
demonstrated both these approaches can lower A.beta. levels, reduce
A.beta. pathology and provide cognitive benefit in various
transgenic models of amyloidosis. Limited studies have also been
conducted in higher species. Caribbean vervet monkeys (16-10 years
old) were immunised with A.beta. peptide over 10 months. A.beta.40
levels were elevated 2-5 fold in the plasma which peaked at 251 d
while the CSF levels of A.beta.40 and A.beta.42 were significantly
decreased by 100 d and returned towards baseline thereafter. This
reduction in CSF was accompanied by a significant reduction in
plaque burden (Lemere, Calif. (2004) Am J Pathology 165: 283-297).
Similar increases in plasma A.beta. levels were also detected
following immunisation of aged (15-20 year old) Rhesus Monkeys
(Gandy, S (2004) Alzheimer Dis Assoc Disord 18: 44:46.
[0009] The first immune therapy targeting brain amyloid was
Elan/Wyeth's AN-1792, an active vaccine. This treatment was
terminated following the development of clinical signs consistent
with meningoencephalitis. Subgroup analyses suggested that
treatment slowed the decline of cognitive function (Nature Clin
Pract Neurol (2005) 1:84-85). Post-mortem analysis of patients also
showed evidence of plaque-clearance (Gilman S. et al, (2005)
Neurology 64 (9) 1553-1562). Bapineuzumab (AAB-001, Elan/Wyeth), a
passive MAb therapy has been shown to significantly improve
cognition scores in a small phase I safety study.
[0010] Other diseases or disorders characterised by elevated
.beta.-amyloid levels or .beta.-amyloid deposits include mild
cognitive impairment (MCI, Blasko I (2006) Neurobiology of aging
"Conversion from cognitive health to mild cognitive impairment and
Alzheimer's disease: Prediction by plasma amyloid beta 42, medial
temporal lobe atrophy and homocysteine" in press, e-published 19
Oct. 2006), hereditary cerebral haemorrhage with .beta.-amyloidosis
of the Dutch type, cerebral .beta.-amyloid angiopathy and various
types of degenerative dementias, such as those associated with
Parkinson's disease, progressive supranuclear palsy, cortical basal
degeneration and diffuse Lewis body type of Alzheimer's disease
(Mollenhauer B (2007) J Neural Transm e-published 23 Feb. 2007, van
Oijen, M Lancet Neurol. 2006 5:655-60) and Down syndrome (Mehta, PD
(2007) J Neurol Sci. 254:22-7).
SUMMARY OF THE INVENTION
[0011] In an embodiment of the present invention there is provided
a therapeutic antibody which is an antibody or antigen binding
fragment and/or derivative thereof which binds .beta.-amyloid
peptide 1-12 (SEQ ID No:15) with equilibrium constant KD less than
100 pM but does not bind to .beta.-amyloid peptide 2-13 (SEQ ID
No:44), both determinations being made in a surface plasmon
resonance assay utilising peptide captured on streptavidin
chip.
[0012] In another embodiment of the present invention there is
provided a therapeutic antibody which is an antibody or antigen
binding fragment and/or derivative thereof which binds
.beta.-amyloid peptide 1-12 (SEQ ID No:15) with equilibrium
constant KD less than 100 pM and has an equilibrium constant KD for
binding to .beta.-amyloid peptide 2-13 (SEQ ID No:44) which is
1000-fold greater than that for peptide 1-12 (SEQ ID No:15), both
determinations being made in a surface plasmon resonance assay
utilising peptide captured on streptavidin chip.
[0013] In another embodiment of the present invention there is
provided a therapeutic antibody which is an antibody or antigen
binding fragment and/or derivative thereof which binds
.beta.-amyloid peptide 1-12 (SEQ ID No:15) with equilibrium
constant KD less than 100 pM and has an equilibrium constant KD for
binding to .beta.-amyloid peptide 2-13 (SEQ ID No:44) which is
10,000-fold greater than that for peptide 1-12 (SEQ ID No:15), both
determinations being made in a surface plasmon resonance assay
utilising peptide captured on streptavidin chip.
[0014] In one aspect the surface plasmon resonance assay utilising
peptide captured on streptavidin chip is the Surface Plasmon
Resonance assay described in the Example below. In another aspect
the surface plasmon resonance assay utilising peptide captured on
streptavidin chip is the Method A(i) described under SPR
Biacore.TM. Analysis below.
[0015] In an alternative embodiment of the present invention there
is provided a therapeutic antibody which is an antibody or antigen
binding fragment and/or derivative thereof which binds
.beta.-amyloid peptide 1-40 with equilibrium constant KD less than
10 nM but does not bind to .beta.-amyloid peptide 2-13 (SEQ ID
No:44), both determinations being made in the surface plasmon
resonance assay described in Method B of the Examples below.
[0016] In another alternative embodiment of the present invention
there is provided a therapeutic antibody which is an antibody or
antigen binding fragment and/or derivative thereof which binds
.beta.-amyloid peptide 1-40 with equilibrium constant KD less than
10 nM and has an equilibrium constant KD for binding to
.beta.-amyloid peptide 2-13 (SEQ ID No:44) which is 1000-fold
greater than that for peptide 1-12 (SEQ ID No:15), both
determinations being made in the surface plasmon resonance assay
described in Method B of the Examples below.
[0017] In another alternative embodiment of the present invention
there is provided a therapeutic antibody which is an antibody or
antigen binding fragment and/or derivative thereof which binds
.beta.-amyloid peptide 1-40 with equilibrium constant KD less than
10 nM and has an equilibrium constant KD for binding to
.beta.-amyloid peptide 2-13 (SEQ ID No:44) which is 10,000-fold
greater than that for peptide 1-12 (SEQ ID No:15), both
determinations being made in the surface plasmon resonance assay
described in Method B of the Examples below.
[0018] In an embodiment of the present invention there is provided
a therapeutic antibody which is an antibody or antigen binding
fragment and/or derivative thereof which binds .beta.-amyloid
peptide and which comprises the following CDRs:
TABLE-US-00001 CDRH1: (SEQ ID No: 1) DNGMA CDRH2: (SEQ ID No: 2)
FISNLAYSIDYADTVTG CDRH3: (SEQ ID No: 3) GTWFAY
within a human heavy chain variable region originating from the VH3
gene family and:
TABLE-US-00002 CDRL1: (SEQ ID No: 4) RVSQSLLHSNGYTYLH CDRL2: (SEQ
ID No: 5) KVSNRFS CDRL3: (SEQ ID No: 6) SQTRHVPYT
within a human light chain variable region originating from the
amino acid sequence disclosed in GenPept entry CAA51135 (SEQ ID
No:24).
[0019] Throughout this specification, the terms "CDR", "CDRL1",
"CDRL2", "CDRL3", "CDRH1", "CDRH2", "CDRH3" follow the Kabat
numbering system as set forth in Kabat et al; Sequences of proteins
of Immunological Interest NIH, 1987. Therefore the following
defines the CDRs according to the invention:
TABLE-US-00003 CDR: Residues CDRH1: 31-35B CDRH2: 50-65 CDRH3:
95-102 CDRL1: 24-34 CDRL2: 50-56 CDRL3: 89-97
[0020] The VH3 gene family and related immunoglobulin gene
nomenclature is described in Matsuda et al (Journal of Experimental
Medicine, 188:2151-2162, 1998) and Lefranc & Lefranc (The
Immunoglobulin Factsbook. 2001. Academic Press: London).
[0021] In a particular embodiment, the human heavy chain variable
region originates from: [0022] A V gene selected from the following
subset of VH3 family members: VH3-48, VH3-21, VH3-11, VH3-7,
VH3-13, VH3-74, VH3-64, VH3-23, VH3-38, VH3-53, VH3-66, VH3-20,
VH3-9 & VH3-43 [0023] A V gene selected from the following
subset of VH3 family members: VH3-48, VH3-21 & VH3-11 [0024]
The VH3-48 gene or an allele thereof.
[0025] The sequence in Genbank entry M99675 is an allele of the
VH3-48 gene. M99675 is a Genbank nucleotide sequence of a genomic
piece of DNA including the two exons that constitute the human
heavy chain gene VH3-48 (SEQ ID No:22) and encode the variable
region amino acid sequence given in SEQ ID No:21. In a particular
aspect the human acceptor heavy chain framework is derived from
M99675.
[0026] In order to construct a complete V-region a framework 4 has
to be added to the germline encoded V-gene M99675. Suitable
framework 4 sequences include that encoded by the human JH4
minigene (Kabat):
TABLE-US-00004 (SEQ ID No: 23) YFDYWGQGTLVTVSS
of which the initial four residues fall within the CDR3 region
which is replaced by the incoming CDR from the donor antibody.
[0027] The skilled person appreciates that a germline V gene and a
J gene do not include coding sequence for the entirety of heavy
chain CDR3. However, in the antibodies of the invention, the CDR3
sequence is provided by the donor immunoglobulin. Accordingly, the
combination of a VH gene such as VH3-48, a JH minigene such as JH4,
and a set of heavy chain CDRs, such as SEQ ID No:1, SEQ ID No:2 and
SEQ ID No:3 (assembled in a manner so as to mimic a mature, fully
rearranged heavy chain variable region) is sufficient to define a
heavy chain variable region of the invention such as that
represented in SEQ ID No:26, 28, 30.
[0028] The variable region encoded by Genpept ID CAA51134 has the
amino acid sequence given in SEQ ID No:24.
[0029] The light chain variable region framework sequence known by
the GenPept ID CAA51134 is the deduced amino acid sequence of a
fully rearranged light chain variable region and is identical to
another amino acid sequence with the same frameworks in the
database: Genpept accession number S40356, and is described in
Klein, R., et al., Eur. J. Immunol. 23 (12), 3248-3262 (1993). The
DNA coding sequence for CAA51134, accessible as Genbank Accesion No
X72467, is given as SEQ ID No: 25.
[0030] In a particular aspect of the invention the human acceptor
heavy chain framework is derived from M99675 and the JH4 minigene
and the human acceptor light chain framework is derived from
CAA51135, optionally containing one or more, such as one to four,
more particularly one to three, substitutions of amino acid
residues based on the corresponding residues found in the donor
V.sub.H domain having the sequence: SEQ ID No:17 and V.sub.L domain
having the sequence: SEQ ID No: 19 that maintain all or
substantially all of the binding affinity of the donor antibody for
.beta.-amyloid peptide.
[0031] By `substantially all of the binding affinity` is meant that
the therapeutic antibody has at most a ten-fold reduction in
binding affinity compared to the donor antibody.
[0032] In a more particular aspect the human acceptor heavy chain
framework derived from M99675 and JH4 has one to four amino acid
residue substitutions selected from positions 24, 48, 93 and/or 94
(Kabat numbering).
[0033] In a more particular aspect of the invention the human
acceptor heavy chain framework derived from M99675 and JH4
comprises the following residues (or a conservative substitute
thereof):
TABLE-US-00005 Position Residue (i) 93 V 94 S or (ii) 24 V 93 V 94
S or (iii) 48 I 93 V 94 S
[0034] In one embodiment of the invention there is provided a
therapeutic antibody comprising a V.sub.H chain having the sequence
set forth in SEQ ID No:26, 28 or 30 and a V.sub.L domain having the
sequence set forth in SEQ ID No:32.
[0035] In another embodiment of the invention there is provided a
therapeutic antibody, which antibody comprises a heavy chain having
the sequence set forth in SEQ ID No:34, 36 or 38 and a light chain
having the sequence set forth in SEQ ID No:40.
[0036] In another embodiment of the invention there is provided a
pharmaceutical composition comprising a therapeutic antibody
according to the invention.
[0037] In a further embodiment of the invention there is provided a
method of treating a human patient afflicted with a .beta.-amyloid
peptide-related disease which method comprises the step of
administering to said patient a therapeutically effective amount of
a therapeutic antibody according to the invention.
[0038] Use of a therapeutic antibody according to the invention in
the manufacture of a medicament for the treatment of a
.beta.-amyloid peptide-related disease is also provided.
[0039] In another embodiment of the invention there is provided a
process for the manufacture of a therapeutic antibody according to
the invention, which process comprises expressing polynucleotide
encoding the antibody in a host cell.
[0040] In another embodiment of the invention there is provided a
polynucleotide encoding a therapeutic antibody heavy chain
comprising a V.sub.H chain having the sequence set forth in SEQ ID
No:26, 28 or 30.
[0041] In another embodiment of the invention there is provided a
polynucleotide encoding a therapeutic antibody light chain
comprising a V.sub.L domain having the sequence set forth in SEQ ID
No:32.
[0042] In another embodiment of the invention there is provided a
polynucleotide encoding a therapeutic antibody heavy chain having
the sequence set forth in SEQ ID No:34, 36 or 38.
[0043] In another embodiment of the invention there is provided a
polynucleotide encoding a therapeutic antibody light chain having
the sequence set forth in SEQ ID No:40.
[0044] In a more particular embodiment of the invention there is
provided a polynucleotide encoding a therapeutic antibody heavy
chain, which polynucleotide comprises the sequence set forth in SEQ
ID No:35, 37, 39 or 42.
[0045] In another more particular embodiment of the invention there
is provided a polynucleotide encoding a therapeutic antibody light
chain, which polynucleotide comprises the sequence set forth in SEQ
ID No:41 or 43.
[0046] In a particular embodiment the therapeutic antibody which is
an antibody or fragment and/or derivative thereof essentially lacks
the functions of a) activation of complement by the classical
pathway; and b) mediating antibody-dependent cellular
cytotoxicity.
[0047] In another embodiment of the invention there is provided an
antibody or a fragment thereof comprising a V.sub.H domain having
the sequence: SEQ ID No:17 and a V.sub.L domain having the
sequence: SEQ ID No: 19.
[0048] In another embodiment of the invention there is provided a
polynucleotide encoding an antibody heavy chain or a fragment
thereof comprising a V.sub.H domain having the sequence SEQ ID
No:17, in particular the polynucleotide of SEQ ID No:18.
[0049] In another embodiment of the invention there is provided a
polynucleotide encoding an antibody light chain or a fragment
thereof comprising a V.sub.L domain having the sequence SEQ ID No:
19, in particular the polynucleotide of SEQ ID No:20.
DETAILED DESCRIPTION OF THE INVENTION
1. Antibody Structures
1.1 Intact Antibodies
[0050] Intact antibodies are usually heteromultimeric glycoproteins
comprising at least two heavy and two light chains. Aside from IgM,
intact antibodies are heterotetrameric glycoproteins of
approximately 150 KDa, composed of two identical light (L) chains
and two identical heavy (H) chains. Typically, each light chain is
linked to a heavy chain by one covalent disulfide bond while the
number of disulfide linkages between the heavy chains of different
immunoglobulin isotypes varies. Each heavy and light chain also has
intrachain disulfide bridges. Each heavy chain has at one end a
variable domain (V.sub.H) followed by a number of constant regions.
Each light chain has a variable domain (V.sub.L) and a constant
region at its other end; the constant region of the light chain is
aligned with the first constant region of the heavy chain and the
light chain variable domain is aligned with the variable domain of
the heavy chain. The light chains of antibodies from most
vertebrate species can be assigned to one of two types called Kappa
and Lambda based on the amino acid sequence of the constant region.
Depending on the amino acid sequence of the constant region of
their heavy chains, human antibodies can be assigned to five
different classes, IgA, IgD, IgE, IgG and IgM. IgG and IgA can be
further subdivided into subclasses, IgG1, IgG2, IgG3 and IgG4; and
IgA1 and IgA2. Species variants exist with mouse and rat having at
least IgG2a, IgG2b. The variable domain of the antibody confers
binding specificity upon the antibody with certain regions
displaying particular variability called complementarity
determining regions (CDRs). The more conserved portions of the
variable region are called framework regions (FR). The variable
domains of intact heavy and light chains each comprise four FR
connected by three CDRs. The CDRs in each chain are held together
in close proximity by the FR regions and with the CDRs from the
other chain contribute to the formation of the antigen binding site
of antibodies. The constant regions are not directly involved in
the binding of the antibody to the antigen but exhibit various
effector functions such as participation in antibody dependent
cell-mediated cytotoxicity (ADCC), phagocytosis via binding to
Fc.gamma. receptor, half-life/clearance rate via neonatal Fc
receptor (FcRn) and complement dependent cytotoxicity via the C1q
component of the complement cascade. The human IgG2 constant region
lacks the ability to activate complement by the classical pathway
or to mediate antibody-dependent cellular cytotoxicity. The IgG4
constant region lacks the ability to activate complement by the
classical pathway and mediates antibody-dependent cellular
cytotoxicity only weakly. Antibodies essentially lacking these
effector functions may be termed `non-lytic` antibodies.
1.1.1 Human Antibodies
[0051] Human antibodies may be produced by a number of methods
known to those of skill in the art. Human antibodies can be made by
the hybridoma method using human myeloma or mouse-human
heteromyeloma cells lines see Kozbor J. Immunol 133, 3001, (1984)
and Brodeur, Monoclonal Antibody Production Techniques and
Applications, pp 51-63 (Marcel Dekker Inc, 1987). Alternative
methods include the use of phage libraries or transgenic mice both
of which utilize human V region repertories (see Winter G, (1994),
Annu. Rev. Immunol 12, 433-455, Green L L (1999), J. Immunol.
methods 231, 11-23).
[0052] Several strains of transgenic mice are now available wherein
their mouse immunoglobulin loci has been replaced with human
immunoglobulin gene segments (see Tomizuka K, (2000) PNAS 97,
722-727; Fishwild D. M (1996) Nature Biotechnol. 14, 845-851,
Mendez M J, 1997, Nature Genetics, 15, 146-156). Upon antigen
challenge such mice are capable of producing a repertoire of human
antibodies from which antibodies of interest can be selected.
[0053] Of particular note is the Trimera.TM. system (see Eren R et
al, (1998) Immunology 93:154-161) where human lymphocytes are
transplanted into irradiated mice, the Selected Lymphocyte Antibody
System (SLAM, see Babcook et al, PNAS (1996) 93:7843-7848) where
human (or other species) lymphocytes are effectively put through a
massive pooled in vitro antibody generation procedure followed by
deconvulated, limiting dilution and selection procedure and the
Xenomouse II.TM. (Abgenix Inc). An alternative approach is
available from Morphotek Inc using the Morphodoma.TM.
technology.
[0054] Phage display technology can be used to produce human
antibodies (and fragments thereof), see McCafferty; Nature, 348,
552-553 (1990) and Griffiths A D et al (1994) EMBO 13:3245-3260.
According to this technique antibody V domain genes are cloned in
frame into either a major or minor coat of protein gene of a
filamentous bacteriophage such as M13 or fd and displayed (usually
with the aid of a helper phage) as functional antibody fragments on
the surface of the phage particle. Selections based on the
functional properties of the antibody result in selection of the
gene encoding the antibody exhibiting those properties. The phage
display technique can be used to select antigen specific antibodies
from libraries made from human B cells taken from individuals
afflicted with a disease or disorder described above or
alternatively from unimmunized human donors (see Marks; J. Mol.
Bio. 222, 581-597, 1991). Where an intact human antibody is desired
comprising a Fc domain it is necessary to reclone the phage
displayed derived fragment into a mammalian expression vectors
comprising the desired constant regions and establishing stable
expressing cell lines.
[0055] The technique of affinity maturation (Marks; Bio/technol
10,779-783 (1992)) may be used to improve binding affinity wherein
the affinity of the primary human antibody is improved by
sequentially replacing the H and L chain V regions with naturally
occurring variants and selecting on the basis of improved binding
affinities. Variants of this technique such as "epitope imprinting"
are now also available see WO 93/06213. See also Waterhouse; Nucl.
Acids Res 21, 2265-2266 (1993).
1.2 Chimaeric and Humanised Antibodies
[0056] The use of intact non-human antibodies in the treatment of
human diseases or disorders carries with it the now well
established problems of potential immunogenicity especially upon
repeated administration of the antibody that is the immune system
of the patient may recognise the non-human intact antibody as
non-self and mount a neutralising response. In addition to
developing fully human antibodies (see above) various techniques
have been developed over the years to overcome these problems and
generally involve reducing the composition of non-human amino acid
sequences in the intact therapeutic antibody whilst retaining the
relative ease in obtaining non-human antibodies from an immunised
animal e.g. mouse, rat or rabbit. Broadly two approaches have been
used to achieve this. The first are chimaeric antibodies, which
generally comprise a non-human (e.g. rodent such as mouse) variable
domain fused to a human constant region. Because the
antigen-binding site of an antibody is localised within the
variable regions the chimaeric antibody retains its binding
affinity for the antigen but acquires the effector functions of the
human constant region and are therefore able to perform effector
functions such as described supra. Chimaeric antibodies are
typically produced using recombinant DNA methods. DNA encoding the
antibodies (e.g. cDNA) is isolated and sequenced using conventional
procedures (e.g. by using oligonucleotide probes that are capable
of binding specifically to genes encoding the H and L chain
variable regions of the antibody of the invention, e.g. DNA of SEQ.
I.D. NO 18 and 20 described supra). Hybridoma cells serve as a
typical source of such DNA. Once isolated, the DNA is placed into
expression vectors which are then transfected into host cells such
as E. Coli, COS cells, CHO cells, PerC6 cells or myeloma cells that
do not otherwise produce immunoglobulin protein to obtain synthesis
of the antibody. The DNA may be modified by substituting the coding
sequence for human L and H chains for the corresponding non-human
(e.g. murine) H and L constant regions see e.g. Morrison; PNAS 81,
6851 (1984). Thus another embodiment of the invention there is
provided a chimaeric antibody comprising a V.sub.H domain having
the sequence: SEQ ID No:17 and a V.sub.L domain having the
sequence: SEQ ID No: 19 fused to a human constant region (which
maybe of a IgG isotype e.g. IgG1).
[0057] The second approach involves the generation of humanised
antibodies wherein the non-human content of the antibody is reduced
by humanizing the variable regions.
[0058] Two techniques for humanisation have gained popularity. The
first is humanisation by CDR grafting. CDRs build loops close to
the antibody's N-terminus where they form a surface mounted in a
scaffold provided by the framework regions. Antigen-binding
specificity of the antibody is mainly defined by the topography and
by the chemical characteristics of its CDR surface. These features
are in turn determined by the conformation of the individual CDRs,
by the relative disposition of the CDRs, and by the nature and
disposition of the side chains of the residues comprising the CDRs.
A large decrease in immunogenicity can be achieved by grafting only
the CDRs of a non-human (e.g. murine) antibodies ("donor"
antibodies) onto a suitable human framework ("acceptor framework")
and constant regions (see Jones et al (1986) Nature 321,522-525 and
Verhoeyen M et al (1988) Science 239, 1534-1536). However, CDR
grafting per se may not result in the complete retention of
antigen-binding properties and it is frequently found that some
framework residues of the donor antibody need to be preserved
(sometimes referred to as "backmutations") in the humanised
molecule if significant antigen-binding affinity is to be recovered
(see Queen C et al (1989) PNAS 86, 10,029-10,033, Co, M et al
(1991) Nature 351, 501-502). In this case, human V regions showing
the greatest sequence homology (typically 60% or greater) to the
non-human donor antibody maybe chosen from a database in order to
provide the human framework (FR). The selection of human FRs can be
made either from human consensus or individual human antibodies.
Where necessary key residues from the donor antibody are
substituted into the human acceptor framework to preserve CDR
conformations. Computer modelling of the antibody maybe used to
help identify such structurally important residues, see
WO99/48523.
[0059] Alternatively, humanisation maybe achieved by a process of
"veneering". A statistical analysis of unique human and murine
immunoglobulin heavy and light chain variable regions revealed that
the precise patterns of exposed residues are different in human and
murine antibodies, and most individual surface positions have a
strong preference for a small number of different residues (see
Padlan E. A. et al; (1991) Mol. Immunol. 28, 489-498 and Pedersen
J. T. et al (1994) J. Mol. Biol. 235; 959-973). Therefore it is
possible to reduce the immunogenicity of a non-human Fv by
replacing exposed residues in its framework regions that differ
from those usually found in human antibodies. Because protein
antigenicity can be correlated with surface accessibility,
replacement of the surface residues may be sufficient to render the
mouse variable region "invisible" to the human immune system (see
also Mark G. E. et al (1994) in Handbook of Experimental
Pharmacology vol. 113: The pharmacology of monoclonal Antibodies,
Springer-Verlag, pp 105-134). This procedure of humanisation is
referred to as "veneering" because only the surface of the antibody
is altered, the supporting residues remain undisturbed. Further
alternative approaches include that set out in WO04/006955 and the
procedure of Humaneering.TM. (Kalobios) which makes use of
bacterial expression systems and produces antibodies that are close
to human germline in sequence (Alfenito-M Advancing Protein
Therapeutics January 2007, San Diego, Calif.).
[0060] It will be apparent to those skilled in the art that the
term "derived" is intended to define not only the source in the
sense of it being the physical origin for the material but also to
define material which is structurally identical to the material but
which does not originate from the reference source. Thus "residues
found in the donor antibody" need not necessarily have been
purified from the donor antibody.
[0061] It is well recognised in the art that certain amino acid
substitutions are regarded as being "conservative". Amino acids are
divided into groups based on common side-chain properties and
substitutions within groups that maintain all or substantially all
of the binding affinity of the therapeutic antibody of the
invention are regarded as conservative substitutions, see the
following Table 1:
TABLE-US-00006 TABLE 1 Side chain Members Hydrophobic met, ala,
val, leu, ile neutral hydrophilic cys, ser, thr Acidic asp, glu
Basic asn, gln, his, lys, arg residues that influence chain gly,
pro orientation aromatic trp, tyr, phe
1.3 Bispecific Antibodies
[0062] A bispecific antibody is an antibody derivative having
binding specificities for at least two different epitopes and also
forms part of the invention. Methods of making such antibodies are
known in the art. Traditionally, the recombinant production of
bispecific antibodies is based on the coexpression of two
immunoglobulin H chain-L chain pairs, where the two H chains have
different binding specificities see Millstein et al, Nature 305
537-539 (1983), WO93/08829 and Traunecker et al EMBO, 10, 1991,
3655-3659. Because of the random assortment of H and L chains, a
potential mixture of ten different antibody structures are produced
of which only one has the desired binding specificity. An
alternative approach involves fusing the variable domains with the
desired binding specificities to heavy chain constant region
comprising at least part of the hinge region, CH2 and CH3 regions.
It is preferred to have the CH1 region containing the site
necessary for light chain binding present in at least one of the
fusions. DNA encoding these fusions, and if desired the L chain are
inserted into separate expression vectors and are then
cotransfected into a suitable host organism. It is possible though
to insert the coding sequences for two or all three chains into one
expression vector. In one preferred approach, the bispecific
antibody is composed of a H chain with a first binding specificity
in one arm and a H-L chain pair, providing a second binding
specificity in the other arm, see WO94/04690. See also Suresh et al
Methods in Enzymology 121, 210, 1986.
[0063] Delivery of therapeutic proteins to the brain has been
hampered by the presence of the blood brain barrier (BBB). Where it
is desired to deliver an antibody of the invention or antibody
fragment of the invention across the BBB various strategies have
been proposed to enhance such delivery where needed.
[0064] In order to obtain required nutrients and factors from the
blood, the BBB posseses some specific receptors, which transport
compounds from the circulating blood to the brain. Studies have
indicated that some compounds like insulin (see Duffy K R et al
(1989) Brain Res. 420:32-38), transferin (see Fishman J B et al
(1987) J. Neurosci 18:299-304) and insulin like growth factors 1
and 2 (see Pardridge W M (1986) Endocrine Rev. 7:314-330 and Duffy
K R et al (1986) Metabolism 37:136-140) traverse the BBB via
receptor-mediated transcytosis. Receptors for these molecules thus
provide a potential means for therapeutic antibodies of the
invention to access the brain using so-called "vectored" antibodies
(see Pardridge W M (1999) Advanced Drug Delivery Review
36:299-321). For example, an antibody to transferrin receptor has
been shown to be dynamically transported into the brain parenchyma
(see Friden P M et al (1991) PNAS 88:4771-4775 and Friden P M et al
(1993) Science 259:373-377). Thus one potential approach is to
produce a bispecific antibody or bispecific fragment such as
described supra wherein a first specificity is towards and a second
specificity towards a transport receptor located at the BBB e.g. a
second specificity towards the transferrin transport receptor.
1.4 Antibody Fragments
[0065] In certain embodiments of the invention there is provided
therapeutic antibody which is an antigen binding fragment. Such
fragments may be functional antigen binding fragments of intact
and/or humanised and/or chimaeric antibodies such as Fab, Fd, Fab',
F(ab').sub.2, Fv, ScFv fragments of the antibodies described supra.
Fragments lacking the constant region lack the ability to activate
complement by the classical pathway or to mediate
antibody-dependent cellular cytotoxicity. Traditionally such
fragments are produced by the proteolytic digestion of intact
antibodies by e.g. papain digestion (see for example, WO 94/29348)
but may be produced directly from recombinantly transformed host
cells. For the production of ScFv, see Bird et al; (1988) Science,
242, 423-426. In addition, antibody fragments may be produced using
a variety of engineering techniques as described below.
[0066] Fv fragments appear to have lower interaction energy of
their two chains than Fab fragments. To stabilise the association
of the V.sub.H and V.sub.L domains, they have been linked with
peptides (Bird et al, (1988) Science 242, 423-426, Huston et al,
PNAS, 85, 5879-5883), disulphide bridges (Glockshuber et al, (1990)
Biochemistry, 29, 1362-1367) and "knob in hole" mutations (Zhu et
al (1997), Protein Sci., 6, 781-788). ScFv fragments can be
produced by methods well known to those skilled in the art see
Whitlow et al (1991) Methods companion Methods Enzymol, 2, 97-105
and Huston et al (1993) Int. Rev. Immunol 10, 195-217. ScFv may be
produced in bacterial cells such as E. Coli but are more typically
produced in eukaryotic cells.
[0067] One disadvantage of ScFv is the monovalency of the product,
which precludes an increased avidity due to polyvalent binding, and
their short half-life. Attempts to overcome these problems include
bivalent (ScFv').sub.2 produced from ScFV containing an additional
C terminal cysteine by chemical coupling (Adams et al (1993) Can.
Res 53, 4026-4034 and McCartney et al (1995) Protein Eng. 8,
301-314) or by spontaneous site-specific dimerization of ScFv
containing an unpaired C terminal cysteine residue (see Kipriyanov
et al (1995) Cell. Biophys 26, 187-204). Alternatively, ScFv can be
forced to form multimers by shortening the peptide linker to
between 3 to 12 residues to form "diabodies", see Holliger et al
PNAS (1993), 90, 6444-6448. Reducing the linker still further can
result in ScFV trimers ("triabodies", see Kortt et al (1997)
Protein Eng, 10, 423-433) and tetramers ("tetrabodies", see Le Gall
et al (1999) FEBS Lett, 453, 164-168). Construction of bivalent
ScFV molecules can also be achieved by genetic fusion with protein
dimerizing motifs to form "miniantibodies" (see Pack et al (1992)
Biochemistry 31, 1579-1584) and "minibodies" (see Hu et al (1996),
Cancer Res. 56, 3055-3061). ScFv-Sc-Fv tandems ((ScFV).sub.2) may
also be produced by linking two ScFv units by a third peptide
linker, see Kurucz et al (1995) J. Immol. 154, 4576-4582.
Bispecific diabodies can be produced through the noncovalent
association of two single chain fusion products consisting of
V.sub.H domain from one antibody connected by a short linker to the
V.sub.L domain of another antibody, see Kipriyanov et al (1998),
Int. J. Can 77,763-772. The stability of such bispecific diabodies
can be enhanced by the introduction of disulphide bridges or "knob
in hole" mutations as described supra or by the formation of single
chain diabodies (ScDb) wherein two hybrid ScFv fragments are
connected through a peptide linker see Kontermann et al (1999) J.
Immunol. Methods 226 179-188. Tetravalent bispecific molecules are
available by e.g. fusing a ScFv fragment to the CH3 domain of an
IgG molecule or to a Fab fragment through the hinge region see
Coloma et al (1997) Nature Biotechnol. 15, 159-163. Alternatively,
tetravalent bispecific molecules have been created by the fusion of
bispecific single chain diabodies (see Alt et al, (1999) FEBS Lett
454, 90-94. Smaller tetravalent bispecific molecules can also be
formed by the dimerization of either ScFv-ScFv tandems with a
linker containing a helix-loop-helix motif (DiBi miniantibodies,
see Muller et al (1998) FEBS Lett 432, 45-49) or a single chain
molecule comprising four antibody variable domains (V.sub.H and
V.sub.L) in an orientation preventing intramolecular pairing
(tandem diabody, see Kipriyanov et al, (1999) J. Mol. Biol. 293,
41-56). Bispecific F(ab')2 fragments can be created by chemical
coupling of Fab' fragments or by heterodimerization through leucine
zippers (see Shalaby et al, (1992) J. Exp. Med. 175, 217-225 and
Kostelny et al (1992), J. Immunol. 148, 1547-1553). Also available
are isolated V.sub.H and V.sub.L domains, see U.S. Pat. No.
6,248,516; U.S. Pat. No. 6,291,158; U.S. Pat. No. 6,172,197.
1.5 Heteroconjugate Antibodies
[0068] Heteroconjugate antibodies are derivatives which also form
an embodiment of the present invention. Heteroconjugate antibodies
are composed of two covalently joined antibodies formed using any
convenient cross-linking methods. See U.S. Pat. No. 4,676,980.
1.6 Other Modifications.
[0069] The interaction between the Fc region of an antibody and
various Fc receptors (Fc.gamma.R) is believed to mediate the
effector functions of the antibody which include antibody-dependent
cellular cytotoxicity (ADCC), fixation of complement, phagocytosis
and half-life/clearance of the antibody. Various modifications to
the Fc region of antibodies of the invention may be carried out
depending on the desired effector property. In particular, human
constant regions which essentially lack the functions of a)
activation of complement by the classical pathway; and b) mediating
antibody-dependent cellular cytotoxicity include the IgG4 constant
region, the IgG2 constant region and IgG1 constant regions
containing specific mutations as for example mutations at positions
234, 235, 236, 237, 297, 318, 320 and/or 322 disclosed in EP0307434
(WO8807089), EP 0629 240 (WO9317105) and WO 2004/014953. Mutations
at residues 235 or 237 within the CH2 domain of the heavy chain
constant region (Kabat numbering; EU Index system) have separately
been described to reduce binding to Fc.gamma.RI, Fc.gamma.RII and
Fc.gamma.RIII binding and therefore reduce antibody-dependent
cellular cytotoxicity (ADCC) (Duncan et al. Nature 1988, 332;
563-564; Lund et al. J. Immunol. 1991, 147; 2657-2662; Chappel et
al. PNAS 1991, 88; 9036-9040; Burton and Woof, Adv. Immunol. 1992,
51; 1-84; Morgan et al., Immunology 1995, 86; 319-324; Hezareh et
al., J. Virol. 2001, 75 (24); 12161-12168). Further, some reports
have also described involvement of some of these residues in
recruiting or mediating complement dependent cytotoxicity (CDC)
(Morgan et al., 1995; Xu et al., Cell. Immunol. 2000; 200:16-26;
Hezareh et al., J. Virol. 2001, 75 (24); 12161-12168). Residues 235
and 237 have therefore both been mutated to alanine residues (Brett
et al. Immunology 1997, 91; 346-353; Bartholomew et al. Immunology
1995, 85; 41-48; and WO9958679) to reduce both complement mediated
and Fc.gamma.R-mediated effects. Antibodies comprising these
constant regions may be termed `non-lytic` antibodies.
[0070] One may incorporate a salvage receptor binding epitope into
the antibody to increase serum half life see U.S. Pat. No.
5,739,277.
[0071] There are five currently recognised human Fc.gamma.
receptors, Fc.gamma.R (I), Fc.gamma.RIIa, Fc.gamma.RIIb,
Fc.gamma.RIIIa and neonatal FcRn. Shields et al, (2001) J. Biol.
Chem 276, 6591-6604 demonstrated that a common set of IgG1 residues
is involved in binding all Fc.gamma.Rs, while Fc.gamma.RII and
Fc.gamma.RIII utilize distinct sites outside of this common set.
One group of IgG1 residues reduced binding to all Fc.gamma.Rs when
altered to alanine: Pro-238, Asp-265, Asp-270, Asn-297 and Pro-239.
All are in the IgG CH2 domain and clustered near the hinge joining
CH1 and CH2. While Fc.gamma.RI utilizes only the common set of IgG1
residues for binding, Fc.gamma.RII and Fc.gamma.RIII interact with
distinct residues in addition to the common set. Alteration of some
residues reduced binding only to Fc.gamma.RII (e.g. Arg-292) or
Fc.gamma.RIII (e.g. Glu-293). Some variants showed improved binding
to Fc.gamma.RII or Fc.gamma.RIII but did not affect binding to the
other receptor (e.g. Ser-267Ala improved binding to Fc.gamma.RII
but binding to Fc.gamma.RIII was unaffected). Other variants
exhibited improved binding to Fc.gamma.RII or Fc.gamma.RIII with
reduction in binding to the other receptor (e.g. Ser-298Ala
improved binding to Fc.gamma.RIII and reduced binding to
Fc.gamma.RII). For Fc.gamma.RIIIa, the best binding IgG1 variants
had combined alanine substitutions at Ser-298, Glu-333 and Lys-334.
The neonatal FcRn receptor is believed to be involved in protecting
IgG molecules from degradation and thus enhancing serum half life
and the transcytosis across tissues (see Junghans R. P (1997)
Immunol. Res 16. 29-57 and Ghetie et al (2000) Annu. Rev. Immunol.
18, 739-766). Human IgG1 residues determined to interact directly
with human FcRn includes Ile253, Ser254, Lys288, Thr307, GIn311,
Asn434 and His435.
[0072] The therapeutic antibody of the invention may incorporate
any of the above constant region modifications.
[0073] In a particular embodiment, the therapeutic antibody
essentially lacks the functions of a) activation of complement by
the classical pathway; and b) mediating antibody-dependent cellular
cytotoxicity. In a more particular embodiment the present invention
provides therapeutic antibodies of the invention having any one (or
more) of the residue changes detailed above to modify
half-life/clearance and/or effector functions such as ADCC and/or
complement dependent cytotoxicity and/or complement lysis.
[0074] In a further aspect of the present invention the therapeutic
antibody has a constant region of isotype human IgG1 with alanine
(or other disrupting) substitutions at positions 235 (e.g. L235A)
and 237 (e.g. G237A) (numbering according to the EU scheme outlined
in Kabat.
[0075] Other derivatives of the invention include glycosylation
variants of the antibodies of the invention. Glycosylation of
antibodies at conserved positions in their constant regions is
known to have a profound effect on antibody function, particularly
effector functioning such as those described above, see for
example, Boyd et al (1996), Mol. Immunol. 32, 1311-1318.
Glycosylation variants of the therapeutic antibodies of the present
invention wherein one or more carbohydrate moiety is added,
substituted, deleted or modified are contemplated. Introduction of
an asparagine-X-serine or asparagine-X-threonine motif creates a
potential site for enzymatic attachment of carbonhydrate moieties
and may therefore be used to manipulate the glycosylation of an
antibody. In Raju et al (2001) Biochemistry 40, 8868-8876 the
terminal sialyation of a TNFR-IgG immunoadhesin was increased
through a process of regalactosylation and/or resialylation using
beta-1,4-galactosyltransferace and/or alpha, 2,3 sialyltransferase.
Increasing the terminal sialylation is believed to increase the
half-life of the immunoglobulin. Antibodies, in common with most
glycoproteins, are typically produced in nature as a mixture of
glycoforms. This mixture is particularly apparent when antibodies
are produced in eukaryotic, particularly mammalian cells. A variety
of methods have been developed to manufacture defined glycoforms,
see Zhang et al Science (2004), 303, 371, Sears et al, Science,
(2001) 291, 2344, Wacker et al (2002) Science, 298 1790, Davis et
al (2002) Chem. Rev. 102, 579, Hang et al (2001) Acc. Chem. Res 34,
727. Thus the invention concerns a plurality of therapeutic
antibodies (which maybe of the IgG isotype, e.g. IgG1) as described
herein comprising a defined number (e.g. 7 or less, for example 5
or less such as two or a single) glycoform(s) of said
antibodies.
[0076] Derivatives according to the invention also include
therapeutic antibodies of the invention coupled to a
non-proteinaeous polymer such as polyethylene glycol (PEG),
polypropylene glycol or polyoxyalkylene. Conjugation of proteins to
PEG is an established technique for increasing half-life of
proteins, as well as reducing antigenicity and immunogenicity of
proteins. The use of PEGylation with different molecular weights
and styles (linear or branched) has been investigated with intact
antibodies as well as Fab' fragments, see Koumenis I. L. et al
(2000) Int. J. Pharmaceut. 198:83-95. A particular embodiment
comprises an antigen-binding fragment of the invention without the
effector functions of a) activation of complement by the classical
pathway; and b) mediating antibody-dependent cellular cytotoxicity;
(such as a Fab fragment or a scFv) coupled to PEG.
2. Production Methods
[0077] Antibodies of the present invention may be produced in
transgenic organisms such as goats (see Pollock et al (1999), J.
Immunol. Methods 231:147-157), chickens (see Morrow K J J (2000)
Genet. Eng. News 20:1-55), mice (see Pollock et al ibid) or plants
(see Doran P M, (2000) Curr. Opinion Biotechnol. 11, 199-204, Ma J
K-C(1998), Nat. Med. 4; 601-606, Baez J et al, BioPharm (2000) 13:
50-54, Stoger E et al; (2000) Plant Mol. Biol. 42:583-590).
Antibodies may also be produced by chemical synthesis. However,
antibodies of the invention are typically produced using
recombinant cell culturing technology well known to those skilled
in the art. A polynucleotide encoding the antibody is isolated and
inserted into a replicable vector such as a plasmid for further
propagation or expression in a host cell. One useful expression
system is a glutamate synthetase system (such as sold by Lonza
Biologics), particularly where the host cell is CHO or NS0 (see
below). Polynucleotide encoding the antibody is readily isolated
and sequenced using conventional procedures (e.g. oligonucleotide
probes). Vectors that may be used include plasmid, virus, phage,
transposons, minichromsomes of which plasmids are a typical
embodiment. Generally such vectors further include a signal
sequence, origin of replication, one or more marker genes, an
enhancer element, a promoter and transcription termination
sequences operably linked to the light and/or heavy chain
polynucleotide so as to facilitate expression. Polynucleotide
encoding the light and heavy chains may be inserted into separate
vectors and introduced (e.g. by transformation, transfection,
electroporation or transduction) into the same host cell
concurrently or sequentially or, if desired both the heavy chain
and light chain can be inserted into the same vector prior to such
introduction.
[0078] It will be immediately apparent to those skilled in the art
that due to the redundancy of the genetic code, alternative
polynucleotides to those disclosed herein are also available that
will encode the polypeptides of the invention.
2.1 Signal Sequences
[0079] Antibodies of the present invention maybe produced as a
fusion protein with a heterologous signal sequence having a
specific cleavage site at the N terminus of the mature protein. The
signal sequence should be recognised and processed by the host
cell. For prokaryotic host cells, the signal sequence may be an
alkaline phosphatase, penicillinase, or heat stable enterotoxin II
leaders. For yeast secretion the signal sequences may be a yeast
invertase leader, a factor leader or acid phosphatase leaders see
e.g. WO90/13646. In mammalian cell systems, viral secretory leaders
such as herpes simplex gD signal and native immunoglobulin signal
sequences (such as human Ig heavy chain) are available. Typically
the signal sequence is ligated in reading frame to polynucleotide
encoding the antibody of the invention.
2.2 Origin of Replication Origin of replications are well known in
the art with pBR322 suitable for most gram-negative bacteria, 2.mu.
plasmid for most yeast and various viral origins such as SV40,
polyoma, adenovirus, VSV or BPV for most mammalian cells. Generally
the SV40 origin of replication component is not needed for
integrated mammalian expression vectors. However the SV40 on may be
included since it contains the early promoter.
2.3 Selection Marker
[0080] Typical selection genes encode proteins that (a) confer
resistance to antibiotics or other toxins e.g. ampicillin,
neomycin, methotrexate or tetracycline or (b) complement
auxotrophic deficiencies or supply nutrients not available in the
complex media or (c) combinations of both. The selection scheme may
involve arresting growth of the host cells that contain no vector
or vectors. Cells, which have been successfully transformed with
the genes encoding the therapeutic antibody of the present
invention, survive due to e.g. drug resistance conferred by the
co-delivered selection marker. One example is the DHFR-selection
system wherein transformants are generated in DHFR negative host
strains (eg see Page and Sydenham 1991 Biotechnology 9: 64-68). In
this system the DHFR gene is co-delivered with antibody
polynucleotide sequences of the invention and DHFR positive cells
then selected by nucleoside withdrawal. If required, the DHFR
inhibitor methotrexate is also employed to select for transformants
with DHFR gene amplification. By operably linking DHFR gene to the
antibody coding sequences of the invention or functional
derivatives thereof, DHFR gene amplification results in concomitant
amplification of the desired antibody sequences of interest. CHO
cells are a particularly useful cell line for this
DHFR/methotrexate selection and methods of amplifying and selecting
host cells using the DHFR system are well established in the art
see Kaufman R. J. et al J. Mol. Biol. (1982) 159, 601-621, for
review, see Werner R G, Noe W, Kopp K, Schluter M, "Appropriate
mammalian expression systems for biopharmaceuticals",
Arzneimittel-Forschung. 48(8):870-80, 1998 August. A further
example is the glutamate synthetase expression system (Bebbington
et al Biotechnology 1992 Vol 10 p 169). A suitable selection gene
for use in yeast is the trp1 gene; see Stinchcomb et al Nature 282,
38, 1979.
2.4 Promoters
[0081] Suitable promoters for expressing antibodies of the
invention are operably linked to DNA/polynucleotide encoding the
antibody. Promoters for prokaryotic hosts include phoA promoter,
Beta-lactamase and lactose promoter systems, alkaline phosphatase,
tryptophan and hybrid promoters such as Tac. Promoters suitable for
expression in yeast cells include 3-phosphoglycerate kinase or
other glycolytic enzymes e.g. enolase, glyceralderhyde 3 phosphate
dehydrogenase, hexokinase, pyruvate decarboxylase,
phosphofructokinase, glucose 6 phosphate isomerase,
3-phosphoglycerate mutase and glucokinase. Inducible yeast
promoters include alcohol dehydrogenase 2, isocytochrome C, acid
phosphatase, metallothionein and enzymes responsible for nitrogen
metabolism or maltose/galactose utilization. Promoters for
expression in mammalian cell systems include RNA polymerase II
promoters including viral promoters such as polyoma, fowlpox and
adenoviruses (e.g. adenovirus 2), bovine papilloma virus, avian
sarcoma virus, cytomegalovirus (in particular the immediate early
gene promoter), retrovirus, hepatitis B virus, actin, rous sarcoma
virus (RSV) promoter and the early or late Simian virus 40 and
non-viral promoters such as EF-1alpha (Mizushima and Nagata Nucleic
Acids Res 1990 18(17):5322. The choice of promoter may be based
upon suitable compatibility with the host cell used for
expression.
2.5 Enhancer Element
[0082] Where appropriate, e.g. for expression in higher
eukaroytics, additional enhancer elements can included instead of
or as well as those found located in the promoters described above.
Suitable mammalian enhancer sequences include enhancer elements
from globin, elastase, albumin, fetoprotein, metallothionine and
insulin. Alternatively, one may use an enhancer element from a
eukaroytic cell virus such as SV40 enhancer, cytomegalovirus early
promoter enhancer, polyoma enhancer, baculoviral enhancer or murine
IgG2a locus (see WO04/009823). Whilst such enhancers are typically
located on the vector at a site upstream to the promoter, they can
also be located elsewhere e.g. within the untranslated region or
downstream of the polydenalytion signal. The choice and positioning
of enhancer may be based upon suitable compatibility with the host
cell used for expression.
2.6 Polvadenvlation/Termination
[0083] In eukaryotic systems, polyadenylation signals are operably
linked to polynucleotide encoding the antibody of this invention.
Such signals are typically placed 3' of the open reading frame. In
mammalian systems, non-limiting example signals include those
derived from growth hormones, elongation factor-1 alpha and viral
(eg SV40) genes or retroviral long terminal repeats. In yeast
systems non-limiting examples of polydenylation/termination signals
include those derived from the phosphoglycerate kinase (PGK) and
the alcohol dehydrogenase 1 (ADH) genes. In prokaryotic system
polyadenylation signals are typically not required and it is
instead usual to employ shorter and more defined terminator
sequences. The choice of polyadenylation/termination sequences may
be based upon suitable compatibility with the host cell used for
expression.
2.7 Other Methods/Elements for Enhanced Yields
[0084] In addition to the above, other features that can be
employed to enhance yields include chromatin remodelling elements,
introns and host-cell specific codon modification. The codon usage
of the antibody of this invention thereof can be modified to
accommodate codon bias of the host cell such to augment transcript
and/or product yield (eg Hoekema A et al Mol Cell Biol 1987
7(8):2914-24). The choice of codons may be based upon suitable
compatibility with the host cell used for expression.
2.8 Host Cells
[0085] Suitable host cells for cloning or expressing vectors
encoding antibodies of the invention are prokaroytic, yeast or
higher eukaryotic cells. Suitable prokaryotic cells include
eubacteria e.g. enterobacteriaceae such as Escherichia e.g. E. Coli
(for example ATCC 31,446; 31,537; 27,325), Enterobacter, Erwinia,
Klebsiella Proteus, Salmonella e.g. Salmonella typhimurium,
Serratia e.g. Serratia marcescans and Shigella as well as Bacilli
such as B. subtilis and B. licheniformis (see DD 266 710),
Pseudomonas such as P. aeruginosa and Streptomyces. Of the yeast
host cells, Saccharomyces cerevisiae, schizosaccharomyces pombe,
Kluyveromyces (e.g. ATCC 16,045; 12,424; 24178; 56,500), yarrowia
(EP402, 226), Pichia Pastoris (EP183, 070, see also Peng et al J.
Biotechnol. 108 (2004) 185-192), Candida, Trichoderma reesia
(EP244, 234), Penicillin, Tolypocladium and Aspergillus hosts such
as A. nidulans and A. niger are also contemplated.
[0086] Although Prokaryotic and yeast host cells are specifically
contemplated by the invention, typically however, host cells of the
present invention are vertebrate cells. Suitable vertebrate host
cells include mammalian cells such as COS-1 (ATCC No. CRL 1650)
COS-7 (ATCC CRL 1651), human embryonic kidney line 293, PerC6
(Crucell), baby hamster kidney cells (BHK) (ATCC CRL. 1632), BHK570
(ATCC NO: CRL 10314), 293 (ATCC NO. CRL 1573), Chinese hamster
ovary cells CHO (e.g. CHO-K1, ATCC NO: CCL 61, DHFR minus CHO cell
line such as DG44 (Urlaub et al, Somat Cell Mol Genet (1986) Vol 12
pp 555-566), particularly those CHO cell lines adapted for
suspension culture, mouse sertoli cells, monkey kidney cells,
African green monkey kidney cells (ATCC CRL-1587), HELA cells,
canine kidney cells (ATCC CCL 34), human lung cells (ATCC CCL 75),
Hep G2 and myeloma or lymphoma cells e.g. NS0 (see U.S. Pat. No.
5,807,715), Sp2/0, Y0.
[0087] Thus in one embodiment of the invention there is provided a
stably transformed host cell comprising a vector encoding a heavy
chain and/or light chain of the therapeutic antibody as described
herein. Typically such host cells comprise a first vector encoding
the light chain and a second vector encoding said heavy chain.
[0088] Such host cells may also be further engineered or adapted to
modify quality, function and/or yield of the antibody of this
invention. Non-limiting examples include expression of specific
modifiying (eg glycosylation) enzymes and protein folding
chaperones.
2.9 Cell Culturing Methods.
[0089] Host cells transformed with vectors encoding the therapeutic
antibodies of the invention may be cultured by any method known to
those skilled in the art. Host cells may be cultured in spinner
flasks, shake flasks, roller bottles, wave reactors (eg System 1000
from wavebiotech.com) or hollow fibre systems but it is preferred
for large scale production that stirred tank reactors or bag
reactors (eg Wave Biotech, Somerset, N.J. USA) are used
particularly for suspension cultures. Typically the stirred tankers
are adapted for aeration using e.g. spargers, baffles or low shear
impellers. For bubble columns and airlift reactors direct aeration
with air or oxygen bubbles maybe used. Where the host cells are
cultured in a serum free culture media this can be supplemented
with a cell protective agent such as pluronic F-68 to help prevent
cell damage as a result of the aeration process. Depending on the
host cell characteristics, either microcarriers maybe used as
growth substrates for anchorage dependent cell lines or the cells
maybe adapted to suspension culture (which is typical). The
culturing of host cells, particularly vertebrate host cells may
utilise a variety of operational modes such as batch, fed-batch,
repeated batch processing (see Drapeau et al (1994) cytotechnology
15: 103-109), extended batch process or perfusion culture. Although
recombinantly transformed mammalian host cells may be cultured in
serum-containing media such media comprising fetal calf serum
(FCS), it is preferred that such host cells are cultured in
serum-free media such as disclosed in Keen et al (1995)
Cytotechnology 17:153-163, or commercially available media such as
ProCHO-CDM or UltraCHO.TM. (Cambrex N.J., USA), supplemented where
necessary with an energy source such as glucose and synthetic
growth factors such as recombinant insulin. The serum-free
culturing of host cells may require that those cells are adapted to
grow in serum free conditions. One adaptation approach is to
culture such host cells in serum containing media and repeatedly
exchange 80% of the culture medium for the serum-free media so that
the host cells learn to adapt in serum free conditions (see e.g.
Scharfenberg K et al (1995) in Animal Cell technology: Developments
towards the 21st century (Beuvery E. C. et al eds), pp 619-623,
Kluwer Academic publishers).
[0090] Antibodies of the invention secreted into the media may be
recovered and purified from the media using a variety of techniques
to provide a degree of purification suitable for the intended use.
For example the use of therapeutic antibodies of the invention for
the treatment of human patients typically mandates at least 95%
purity as determined by reducing SDS-PAGE, more typically 98% or
99% purity, when compared to the culture media comprising the
therapeutic antibodies. In the first instance, cell debris from the
culture media is typically removed using centrifugation followed by
a clarification step of the supernatant using e.g. microfiltration,
ultrafiltration and/or depth filtration. Alternatively, the
antibody can be harvested by microfiltration, ultrafiltration or
depth filtration without prior centrifugation. A variety of other
techniques such as dialysis and gel electrophoresis and
chromatographic techniques such as hydroxyapatite (HA), affinity
chromatography (optionally involving an affinity tagging system
such as polyhistidine) and/or hydrophobic interaction
chromatography (HIC, see U.S. Pat. No. 5,429,746) are available. In
one embodiment, the antibodies of the invention, following various
clarification steps, are captured using Protein A or G affinity
chromatography followed by further chromatography steps such as ion
exchange and/or HA chromatography, anion or cation exchange, size
exclusion chromatography and ammonium sulphate precipitation.
Typically, various virus removal steps are also employed (e.g.
nanofiltration using e.g. a DV-20 filter). Following these various
steps, a purified (typically monoclonal) preparation comprising at
least 10 mg/ml or greater e.g. 100 mg/ml or greater of the antibody
of the invention is provided and therefore forms an embodiment of
the invention. Concentration to 100 mg/ml or greater can be
generated by ultracentrifugation. Suitably such preparations are
substantially free of aggregated forms of antibodies of the
invention.
[0091] Bacterial systems are particularly suited for the expression
of antibody fragments. Such fragments are localised intracellularly
or within the periplasma. Insoluble periplasmic proteins can be
extracted and refolded to form active proteins according to methods
known to those skilled in the art, see Sanchez et al (1999) J.
Biotechnol. 72, 13-20 and Cupit P M et al (1999) Lett Appl
Microbiol, 29, 273-277.
3. Pharmaceutical Compositions
[0092] Purified preparations of antibodies of the invention
(particularly monoclonal preparations) as described supra, may be
incorporated into pharmaceutical compositions for use in the
treatment of human diseases and disorders such as those outlined
above. Typically such compositions further comprise a
pharmaceutically acceptable (i.e. inert) carrier as known and
called for by acceptable pharmaceutical practice, see e.g.
Remingtons Pharmaceutical Sciences, 16th ed, (1980), Mack
Publishing Co. Examples of such carriers include sterilised carrier
such as saline, Ringers solution or dextrose solution, buffered
with suitable buffers such as sodium acetate trihydrate to a
pharmaceutically acceptable pH, such as a pH within a range of 5 to
8. Pharmaceutical compositions for injection (e.g. by intravenous,
intraperitoneal, intradermal, subcutaneous, intramuscular or
intraportal) or continuous infusion are suitably free of visible
particulate matter and may comprise from 1 mg to 10 g of
therapeutic antibody, typically 5 mg to 1 g, more specifically 5 mg
to 25 mg or 50 mg of antibody. Methods for the preparation of such
pharmaceutical compositions are well known to those skilled in the
art. In one embodiment, pharmaceutical compositions comprise from 1
mg to 10 g of therapeutic antibodies of the invention in unit
dosage form, optionally together with instructions for use.
Pharmaceutical compositions of the invention may be lyophilised
(freeze dried) for reconstitution prior to administration according
to methods well known or apparent to those skilled in the art.
Where embodiments of the invention comprise antibodies of the
invention with an IgG1 isotype, a chelator of metal ions including
copper, such as citrate (e.g. sodium citrate) or EDTA or histidine,
may be added to the pharmaceutical composition to reduce the degree
of metal-mediated degradation of antibodies of this isotype, see
EP0612251. Pharmaceutical compositions may also comprise a
solubiliser such as arginine base, a detergent/anti-aggregation
agent such as polysorbate 80, and an inert gas such as nitrogen to
replace vial headspace oxygen.
[0093] Effective doses and treatment regimes for administering the
antibody of the invention are generally determined empirically and
are dependent on factors such as the age, weight and health status
of the patient and disease or disorder to be treated. Such factors
are within the purview of the attending physician. Guidance in
selecting appropriate doses may be found in e.g. Smith et al (1977)
Antibodies in human diagnosis and therapy, Raven Press, New York
but will in general be 1 mg to 10 g. In one embodiment, the dosing
regime for treating a human patient is 1 mg to 1 g of therapeutic
antibody of the invention administered subcutaneously once per week
or every two weeks, or by intravenous infusion every 1 or 2 months.
Such a dosage corresponds to 0.014-140 mg/kg, such as 0.014-14
mg/kg. Compositions of the present invention may also be used
prophylatically.
4. Clinical Uses.
[0094] It will be appreciated that diseases characterised by
elevated .beta.-amyloid levels or .beta.-amyloid deposits include
Alzheimer's disease, mild cognitive impairment, Down's syndrome,
hereditary cerebral haemorrhage with .beta.-amyloidosis of the
Dutch type, cerebral .beta.-amyloid angiopathy and various types of
degenerative dementias, such as those associated with Parkinson's
disease, progressive supranuclear palsy, cortical basal
degeneration and diffuse Lewis body type of Alzheimer's
disease.
[0095] Most preferably, the disease characterised by elevated
.beta.-amyloid levels or .beta.-amyloid deposits is Alzheimer's
disease.
[0096] Although the present invention has been described
principally in relation to the treatment of human diseases or
disorders, the present invention may also have applications in the
treatment of similar diseases or disorders in non-human
mammals.
Examples
Methods
[0097] Biacore.TM./Biacore 3000 a device that allows measurement of
real time kinetics of molecular interactions using SPR [0098] SPR
(surface plasmon resonance)--physical phenomenon employed by
Biacore.TM. instruments for measurement of mass changes on sensor
chip [0099] CM5 Biacore.TM. sensor chip with general purpose
surface coated with a carboxymethylated dextran matrix [0100] ELISA
enzyme linked immunosorbent assay [0101] SRU SRU BIND.TM. Biosensor
technology allowing to monitor label-free biochemical interactions
[0102] Integra CL1000 Mini-bioreactors sold by IBS Integra
Biosciences [0103] FMAT fluorometric microvolume assay technology
(Applied Biosystems) [0104] ABi8200 Applied Biosystems 8200
fluorescence macro confocal cellular detection system for FMAT
[0105] FPLC Fast protein liquid chromatography [0106] ProSepA
HiTrap Protein A columns for FPLC sold by GE Healthcare
Materials
[0106] [0107] DMSO dimethylsulphoxide [0108] HEPES
N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) [0109] EDTA
ethylenediaminetetraacetic acid [0110] Tris
HCl--tris-(hydroxymethyl)aminomethane hydrochloride [0111]
NaCl--sodium chloride [0112] Tween-20--polyoxyethylenesorbitan
monolaurate [0113] BSA--bovine serum albumin [0114] PBS--phosphate
buffered saline [0115] PFA--paraformaldehyde [0116] IMS--industrial
methylated spirit [0117] DAB--3,3'diaminobenzidine [0118] DMEM
dulbecco's modified eagle's medium [0119] FCS fetal calf serum
[0120] Opti-MEM modified eagle's medium based medium by
Invitrogen/Gibco [0121] Lipofectamine cationic lipid based cell
transfection agent sold by Invitrogen/Gibco [0122] Transfast
liposomal transfection agent sold by Promega [0123] Versene metal
ion chelating agent (ethylenediaminetetraacetic acid) [0124]
Glutamax stable form of glutamine added to culture medium
(dipeptide L-Ananyl-L-Glutamine supplement) [0125] Histoclear
tissue clearing agent [0126] HBS-EP buffer General purpose
Biacore.TM. buffer containing 0.01M HEPES pH7.4, 0.15M NaCl, 3 mM
EDTA, 0.005% Surfactant P20
Generation of Mouse Monoclonal Antibody 2E7
[0127] Mouse monoclonal antibody 2E7 was generated from a
conventional immunisation of mice. Mice were immunised with soluble
or aggregated .beta.-amyloid 1-40 and 1-42 formulated in Freund's
adjuvant. Following final boost without adjuvant, splenocytes were
fused with myeloma cells. Fused cells were grown in 96-well plates
from which hybridoma supernatants were screened for potential
leads. Selected antibody 2E7, which was obtained from the
immunisation with soluble .beta.-amyloid 1-40, was of murine IgG2a
isotype and had beta-amyloid binding activity in the efflux assay
described below and an affinity of 36.1 pM for beta-amyloid 1-40
when measured by Biacore.TM., Method A(i) (Table 10A).
Epitope Mapping of 2E7
[0128] In order to finely map the binding of antibody 2E7 to the
.beta.-amyloid peptide, a peptide set (A) was utilised. Peptide set
(A) consisted of a set of 31 12-mer overlapping peptides covering
the complete sequence of the .beta.-amyloid 1-42 peptide. Each
sequential peptide was initiated at the sequential amino acid
within the .beta.-amyloid peptide, thus shifting the sequence
covered between sequential peptides by a single amino acid. All
peptides in set (A) contained a 3 amino acid C-terminal linker
(glycine-serine-glycine) and a terminal biotinylated lysine
residue. In addition, all peptides except peptide A.beta.1
DAEFRHDSGYEVGSGK-biotin (SEQ ID No:15) were N-terminally
acetylated. A second set of peptides (set (B)) consisted of
sequential one amino acid C-terminal deletions from a peptide
containing amino acids 1 to 10 of the .beta.-amyloid sequence. All
peptides in set (B) contained a 3 amino acid C-terminal linker
(glycine-serine-glycine) and a terminal biotinylated lysine
residue, but with additional glycine and serine residues to replace
for deleted .beta.-amyloid amino acids (Table 2). Thus all peptides
in set (B) are of the same length.
TABLE-US-00007 TABLE 2 Sequences of biotinylated peptides (set (B)
that contained truncated N-terminal fragments of .beta.-amyloid
DAEFRHDSGYGSGGSK-biotin (SEQ ID No: 7) DAEFRHDSG--GSGSGSK-biotin
(SEQ ID No: 8) DAEFRHDS--GSGGSGGK-biotin (SEQ ID No: 9)
DAEFRHD--GSGGSGGSK-biotin (SEQ ID No: 10) DAEFRH--GSGGSGGSGK-biotin
(SEQ ID No: 11) DAEFR--GSGGSGGSGSK-biotin (SEQ ID No: 12)
DAEF--GSGGSGGSGGSK-biotin (SEQ ID No: 13) DAE--GSGGSGGSGGSGK-biotin
(SEQ ID No: 14)
Monitoring the Binding of 2E7 to .beta.-Amyloid Derived Peptides
Using Optical Biosensors
[0129] 96-well SRU Bind.TM. streptavidin-coated plates (SRU
Biosystems) were washed with PBS containing 1% DMSO to remove
glycerol and preservative. A volume of 50 ul/well was left to
equilibrate to room temperature to provide a constant base line.
Biotinylated peptides were diluted to approx. 0.3 ug/ml in PBS
containing 1% DMSO and 50 ul of each added to wells and incubated
for approximately 1 h. Replicate wells were prepared using
different sectors of the plate and at least one no-peptide control
well was used in each sector to reference subtract the data. After
peptide capture the plate was washed with PBS containing 1% DMSO,
leaving 50 ul of fresh buffer per well to provide a new base line
on the reader. No decay of peptide from the surface was seen. The
buffer was then replaced with 40 ul/well buffer containing test
antibody at 20-64 nM. for 2 hours. It was found that antibody 2E7
only bound to the peptide encompassing amino acids 1-12 of the
.beta.-amyloid peptide in peptide set (A) (peptide A.beta.1, SEQ ID
No:15) This result implies that the aspartic acid at residue 1 is
critical for binding to this peptide.
[0130] In order to further characterise the binding site of
antibody 2E7, peptide set (B) was utilised. Using SRU BIND.TM.
biosensor methodology antibody 2E7 showed negligible binding to the
peptides encompassing amino acids 1-3 and 1-4 of the .beta.-amyloid
peptide (SEQ ID No:14 and 13). Binding to a peptide encompassing
amino acids 1-7 of the .beta.-amyloid peptide (SEQ ID No:10) was
comparable to the peptide encompassing amino acids 1-12 of the
.beta.-amyloid peptide (from peptide set (A)). Binding to peptides
encompassing amino acids 1-5 or 1-6 of the .beta.-amyloid peptide
(SEQ ID No:12 or 11) was observed, but was weaker (as measured by
stability after an additional washing step) than the binding to the
peptide encompassing amino acids 1-7 of the .beta.-amyloid peptide
(SEQ ID No:10).
[0131] Thus it has been shown that only residues 1-7 of the
.beta.-amyloid peptide are required for full binding as measured
using this methodology.
Surface Plasmon Resonance Assay
[0132] In addition to the experiments described above, the
Biacore.TM. 3000 optical biosensor was used to monitor the binding
of 2E7 antibody to selected .beta.-amyloid sequence derived
peptides. Binding was measured by injecting test antibodies at up
to 64 nM for 5 minute over peptides captured on separate
streptavidin chip surfaces (130-230 RU (resonance units)). A
running buffer (HBS-EP) containing 0.01M HEPES pH7.4, 0.15M NaCl, 3
mM EDTA and 0.005% Surfactant P20.TM. at 25.degree. C. was used at
a flow rate of 20 ul/min. All runs were double referenced against a
blank streptavidin surface and blank injections. Analysis was
carried out using the Biacore.TM. analysis software
BIAevaluation.TM. version 4.1. Results from selected peptides in
set (A) further confirmed the SRU BIND.TM. derived data indicating
that 2E7 bound only to the peptide encompassing amino acids 1-12
(SEQ ID No:15) of the .beta.-amyloid peptide with an apparent
equilibrium constant KD of approximately 50 pM. Under the same
conditions, 2E7 did not bind to the peptide encompassing amino
acids 2-13 of the .beta.-amyloid peptide.
TABLE-US-00008 Peptide A.beta.2-13 (SEQ ID No: 44)
AEFRHDSGYEVHGSGK-biotin
[0133] The experimental method and conditions used allowed the
detection of high but also lower affinity molecules--in the same
experimental setup, by contrast to 2E7, another antibody
recognising an N-terminal epitope of the .beta.-amyloid peptide was
shown to bind the 2-13 peptide (SEQ ID No:44) with an apparent KD
of 7 nM. 2E7 did not bind to a selection of peptides in set (A)
from mid regions of the .beta.-amyloid peptide. In a separate
experiment the .beta.-amyloid 1-40 peptide was captured via its
N-terminal aspartic acid residue that had been biotinylated. This
peptide was captured onto a Biacore.TM. streptavidin coated chip as
previously described. Antibody 2E7 injected at 66 nM for 1 minute
could not bind this peptide. Therefore, it is concluded that the
previously described N-terminal binding site was masked by the
linker and capture method, thus further confirming the extreme
N-terminus as containing the core binding site
Binding to Cell Expressed Amyloid Precursor Protein (APP)
[0134] .beta.-Amyloid is composed of peptides formed by proteolytic
cleavage of a type I transmembrane precursor protein named amyloid
precursor protein (APP). As APP has a large extracellular domain,
binding to this protein could potentially initiate an
antibody-dependent cellular cytotoxicity reaction (ADCC).
[0135] To characterise binding of antibody to cell-surface full
length APP an FMAT.TM. ABI8200 based assay was utilised.
Transfection of HEK293T Cells with Wild Type APP DNA
[0136] HEK293T cells are maintained in DMEM F12 medium containing
10% (v/v) FCS and 1.times. Glutamax. Cells are seeded in 75
cm.sup.2 tissue culture flasks and grown to 60-80% confluency
(18-24 h) prior to transfection. For transfection, 9 ug of DNA,
(either wild type APP DNA (in PCDNA3.1 (Invitrogen) vector), or
vector only controls), is mixed with 0.3 ml of Opti-MEM.TM. media.
30 ul Lipofectamine.TM. transfection agent is mixed with 0.3 ml
Opti-MEM.TM. media and the two mixtures pooled. The pooled mixtures
are incubated at room temperature for 30 min prior to the addition
of a further 4.8 ml of Opti-MEM.TM. media. The final mixture is
added to the cells (post washing with Opti-MEM.TM. media) for 5 h
and 6 ml of 10% (v/v) newborn calf serum in DMEM is then added. 48
hrs post transfection, supernatant is removed and the monolayer
washed in versene, and then 3 ml of Versene.TM. chelating agent is
added to each flask, incubated for 5 mins at 37 C, and the detached
cells pelleted at 200 g for 5 mins. The resultant cell pellet is
gently resuspended in 1 ml of assay buffer (2% heat treated serum,
0.5% BSA, 0.1% NaN.sub.3 in PBS pH7.4, filtered through a 0.2 um
filter) to create a single cell suspension.
FMAT.TM. ABI8200 Based Assay Test antibodies (2E7, LN27 (Zymed)
mouse IgG to extracellular domain of APP as a positive control, and
an antibody G210 which recognises the x-40 form of the
.beta.-amyloid peptide as a negative control) were diluted to 10
.mu.g/ml in sterile filtered assay buffer (2% heat treat serum,
0.5% BSA, 0.1% NaN.sub.3 in PBS pH7.2) in a polypropylene plate,
and then a further six serial 1:1 dilutions were performed down the
plate. Assay buffer only was used as a blank. 50 ul of a suspension
of HEK293T cells transfected with wild type APP DNA (Experiment 1:
10,000 cells; Experiment 2: 20,000 cells) was added to each well of
a 96 well plate, to which 5 ul of each of the antibody solutions
were added to duplicate wells. 50 ul/well of F-MAT.TM. blue anti
mouse IgG stock, (antibody is labelled using F-MAT.TM. blue
monofunctional reactive dye kit from ABI, 4328408), diluted 1:500
(Experiment 1) and 1:1000 (Experiment 2) in assay buffer, was then
added to each well and the plate briefly shaken and left to settle
for 1 hr. The plate was then read using the ABI 8200 fluorescence
macro confocal cellular detection system (Applied Biosystems).
[0137] Derived counts data were then interpreted using Excel.TM.
spreadsheet software. Briefly, mock transfected counts were
subtracted from the full length APP transfected cell counts to
obtain a specific signal for each antibody. Two antibody
concentrations that were on the linear part of the curve were
chosen (1.25 and 0.63 ug/ml) and the background corrected derived
counts at these concentrations expressed as the percentage of the
LN27 antibody binding, and averaged over the two antibody
concentrations. The resultant data is described in Table 3 (% of
LN27 binding.+-.SE)
[0138] Thus, within this assay system, the binding of 2E7 to cell
surface APP is indistinguishable from that of the negative control
antibody G210.
TABLE-US-00009 TABLE 3 antibody Experiment 1 Experiment 2 LN27
100.0 .+-. 7.1 100.0 .+-. 4.7 G210 5.5 .+-. 1.3 2.0 .+-. 1.6 2E7
9.9 .+-. 3.7 2.2 .+-. 1.4
Binding to Amyloid Precursor Protein Derived Peptide
[0139] The previously described epitope mapping studies have shown
that antibody 2E7 binds to the extreme N-terminus of the
.beta.-amyloid peptide, with the aspartic acid residue at position
1 being essential for binding. This suggests that the antibody
recognises a `neo` epitope formed by cleavage of APP at the
.beta.-secretase site. This observation would suggest that antibody
2E7 should not recognise adjacent APP peptide sequence. To test
this hypothesis an APP peptide (Peptide APP1, SEQ ID No:16) was
synthesised which included residues 1-7 of the .beta.-amyloid
peptide and the five adjacent APP derived amino acids. Thus peptide
APP1 contained contiguous amino acids from position 5 N-terminal to
the BACE-1 cleavage site to position 7 C-terminal to the BACE-1
cleavage site and was N-terminally acetylated. The ability of
antibody 2E7 to bind to the APP derived peptide APP1 and the
.beta.-amyloid 1-12 peptide (peptide A.beta.1) was compared using
Biacore.TM. methodology (as previously described for epitope
mapping). Antibody 2E7 showed high affinity binding to the
.beta.-amyloid peptide A.beta.-1, which contains the basic epitope
1-7. However, no binding was observed to the APP1 peptide which
also contains the basic .beta.-amyloid derived sequence 1-7.
TABLE-US-00010 Peptide A.beta.1 SEQ ID No: 15
DAEFRHDSGYEVGSGK-biotin APP1 SEQ ID No: 16
AcNH-SEVKMDAEFRHDGSGK-biotin
[0140] A combination of FMAT.TM. based cellular binding and
Biacore.TM. based peptide mapping has been utilised to show that,
in these formats, 2E7 has no binding affinity for the full length
APP protein. Given that the aspartic acid residue at position 1 of
the .beta.-amyloid peptide is required for binding, it is concluded
that 2E7 only recognises the `neo` N-terminus of .beta.-amyloid and
hence should not bind cell surface expressed APP.
In Vivo Biological Activity
I.sup.125 .beta.-Amyloid Efflux Model
[0141] A number of published studies have shown that .beta.-amyloid
antibodies can form complexes with .beta.-amyloid peptide in the
bloodstream. It is argued that this sequestration of peripheral
.beta.-amyloid allows for further efflux of CNS amyloid into the
bloodstream (DeMattos R B, PNAS (2001), 98(15); 8850-8855). An
acute pharmacodynamic model was developed to screen antibodies for
their ability to complex with brain derived .beta.-amyloid peptide
in the bloodstream.
[0142] Anaesthesia (4% isoflurane) was induced in male C57/BL6J
mice and maintained (1.5% isoflurane) in 100% oxygen. Animals were
then placed in a stereotaxic frame. Following midline incision
along the sagittal suture a bore hole was drilled through the skull
and a guide cannula was inserted into the lateral cerebral
ventricle (co-ordinates anterioposterior (AP) -0.5 mm, lateral (L)
+0.7 mm, ventral (V) -2.5 mm). A further two bore holes were
drilled through the skull into which cortical screws were placed.
The cannula was anchored in place by cyanoacrylate gel and the
incision was sutured around the cyanoacrylate gel headcap.
Post-operatively the mice received 0.3 ml saline subcutaneously and
were placed in a warm environment to recover from anaesthesia. On
recovery of the righting reflex, mice were housed singly and
received 5 days standard post-op care. No procedures were permitted
for a further 5 days or until pre-operative body weight was
regained. Following recovery, cannula placement was verified by the
angiotensin II drinking response. Each mouse received an
intracerebroventricular (ICV) administration (5 .mu.l) of 100 ng
angiotensin II (AII) (made up in 0.9% saline). Following
administration of AII, water intake was observed for 15 minutes.
Mice with a positive dipsogenic response to AII (sustained
drinking) were included in the studies, which commenced no sooner
than five days post AII injection.
[0143] On the day of study the mice were placed for 5-10 minutes in
a warm environment to induce vasodilation, necessary for ease of
injection into the tail vein. Test antibody (600 .mu.g) or PBS
vehicle (dose volume no greater than 10 ml per kg body weight) was
injected via the tail vein and mice were returned to their
individual cages post-injection. At exactly one hour post tail vein
injection, mice were slowly ICV injected (2 .mu.l per minute) with
2 ng (1 .mu.Ci) of I.sup.125 beta-amyloid 1-40 (Amersham
Biosciences, UK) in a dose volume of 5 .mu.l. At exactly four hours
post ICV dose, 50 .mu.l of trunk blood was collected and the
radioactivity level measured on a scintillation counter.
[0144] Mice that had been injected into the tail-vein with 2E7 (n=6
per treatment group) showed a statistically significant increase in
the radioactive signal (counts per minute--CPM) in 50 .mu.l of
trunk blood compared with the CPM signal detected in vehicle
injected mice--(CPM-vehicle: 1339.7.+-.496.2 vs. 2E7
4387.9.+-.980.3; ANOVA:F (2,13)=4.97, p<0.05. Post-hoc LSD:
p=0.01 2E7 vs. vehicle [post-hoc Duncans: p=0.02 2E7 vs,
vehicle]).
[0145] In two further studies with 2E7 conducted with the identical
protocol, similar increases in amyloid efflux into blood when
compared with vehicle injected controls were observed (CPM blood:
Vehicle 352+/-113 versus 2E7 2397+/-353, and Vehicle 1281+/-312
versus 2E7 5291+/-885; ANOVA with post-hoc LSD test p<0.001 vs.
vehicle).
Transgenic CNS .beta.-Amyloid Lowering Models
[0146] 1. .beta.-Amyloid Load following 4 week dosing of 2 month
old TASTPM mice
[0147] Male and female TASTPM transgenic mice (double-mutant
APPswe.times.PS1.M146V, Howlett D R (2004) Brain Research 1017
(1-2) 130-136) aged between 61 and 65 days at the start of the
study and were singly housed. Equal numbers of mice were assigned
to each treatment group (N=12 per group) and were randomized
according to gender and age. Treatment groups comprised the
following: A: MOPC21 (antibody with unknown specificity, Holton et
al (1987) J. Immunol 139(9) 3041-3049, negative control), B: 2E7
(test antibody). AII antibodies were dissolved in PBS and were
dosed by the intraperitoneal route. Irrespective of animal weight,
300 ug of antibody was administered. Animals were dosed twice
weekly for four weeks. One day after the final dose, animals were
euthanased by overdose with sodium pentobarbital. Brains were
dissected and hemisected. Hemisected brain samples were collected
into pre-weighed 2 ml Eppendorf.TM. tubes and snap frozen. Samples
were subsequently thawed, reweighed and 1 ml of 5M guanidine HCl
containing Complete protease Inhibitor.TM. tablets (Boehringer
Mannheim) added, before the samples were homogenized and incubated
at 4.degree. C. for >90 min with constant agitation.
[0148] Samples were then diluted 1 in 10 into assay buffer (50 mM
Tris HCl, pH7.4, 150 mM NaCl, 0.05% Tween-20+1% BSA), vortexed and
spun at 20,000 G for 20 mins at 4.degree. C. The supernatant was
removed and added as triplicate samples to the assay plate.
[0149] The levels of A.beta.40 and A.beta.42 were measured using a
sensitive plate based electrochemiluminescent immunoassay
(BioVeris.TM.) employing C-terminal specific .beta.-amyloid
antibodies (to A.beta.40 or A.beta.42) labelled with Oritag.TM.
specific label to facilitate detection (BioVeris.TM.) used to
capture either A.beta.40 or A.beta.42, along with a biotinylated
N-terminal specific A.beta. antibody. Antibody-A.beta. complexes
were captured with streptavidin coated beads that bind biotinylated
antibodies (Dynabeads.TM., Dynal) incubated overnight at room
temperature with vigorous mixing and assayed in a BioVeris.TM. M8
photodetector. Standard curves were constructed using human
A.beta.40 and A.beta.42 peptides in assay buffer containing the
required concentration of Guanidine HCl. Data was analysed using
Excel Robosage.TM. statistical analysis software and A.beta. levels
expressed as pmole/g tissue.
[0150] In this paradigm, treatment with 2E7 antibody reduced CNS
A.beta.42 load by 37% (p<0.001). and CNS A.beta.40 by 23%
(p<0.001).
[0151] In subsequent studies under similar experimental conditions,
2E7 antibody reduced CNS A.beta.42 load by 38% (Study 1, males
only), 22% (Study 2, non-significant) and 39% (Study 3, males,
p=0.001) and 13% (Study 3, females, non-significant) when compared
to PBS treated animals. In these studies 2E7 also reduced CNS
A.beta.40 by 18% (Study 3, males, p=0.017) and offered a
non-significant reduction in CNS A.beta.40 by 25% (Study 1, males
only), <1% (Study 2) and a non-significant increase of 3% (Study
3, females) when compared to PBS treated animals.
2. .beta.-Amyloid Load Following 4 Month Dosing of 4 Month Old
TASTPM Mice
[0152] Briefly, 4 month old TASTPM transgenic mice were dosed 300
.mu.g of antibody once or twice weekly via an intraperitonial
(i.p.) route. After 4 months of dosing CNS .beta.-amyloid levels
were measured by ELISA and plaque load was measured by
immunohistochemistry. Between the ages of 4 and 8 months, the CNS
.beta.-amyloid load increases exponentially and consequently,
plaque pathology rapidly develops (Howlett D R (2004) Brain
Research 1017 (1-2) 130-136).
[0153] Mice were aged between 120 and 128 days at the start of the
study and were singly housed. Similar numbers of mice were assigned
to each treatment group (N=20 or 21 per group) and were randomized
according to gender and age. Treatment groups comprised the
following: A: PBS (vehicle) dosed twice weekly, B: 2E7 dosed once
weekly, C: 2E7 dosed twice weekly, D: PBS dosed once weekly. A 300
microgram dose (79 microlitres volume) of 2E7 was administered via
the intraperitoneal route. Vehicle treated animals received the
same volume of PBS. Animals were dosed for eighteen weeks. TASTPM
mice are liable to suffer spontaneous seizures and as a result a
number of animals died during the course of the study. Final
numbers were as follows A: 4 females, 9 males; B: 5 females, 8
males; C: 4 females, 9 males; D: 2 females, 9 males. Two or four
days after the final dose (equal numbers per group) animals were
euthanased by overdose with sodium pentobarbital. A tail tip sample
from each mouse was taken for confirmation of the genotype. Brains
were dissected and hemisected. The right hemisphere was fixed by
immersion in 4% paraformaldehyde and processed for histology. The
left hemisphere was collected into pre-weighed 2 ml Eppendorf.TM.
tubes, frozen on dry ice and stored at -80.degree. C. for
subsequent analysis of amyloid content. Prior to analysis, samples
were thawed, reweighed and 1 ml of 5M guanidine HCl containing
Complete protease Inhibitor.TM. tablets (Boehringer Mannheim)
added, before the samples were homogenized and incubated at
4.degree. C. for >90 min with constant agitation.
[0154] Samples were then diluted 1 in 10 into assay buffer (50 mM
Tris HCl, pH7.4, 150 mM NaCl, 0.05% Tween-20+1% BSA), vortexed and
spun at 20,000 G for 20 mins at 4.degree. C. The supernatants were
diluted a further 1:1000 and added as triplicate samples to the
assay plate.
[0155] The levels of A.beta.40 and A.beta.42 were measured as for
the 4 week dosing study.
[0156] An analysis of variance was used with treatment, sex and
dosing schedule included in the model as fixed effects. All of the
interactions between the three factors were also included. There
were no significant differences between the two dosing schedules
(once or twice weekly). With this experimental design, firstly it
could be assessed if there were any significant differences between
the dosing schedules and secondly, as there were no such
significant differences, data from the two dosing schedules could
be combined, thus increasing the power of the experiment by
doubling the number of mice in the analysis.
[0157] In this paradigm, treatment with 2E7 antibody reduced CNS
A.beta.42 load by 22.5% (p=0.0152). Levels of CNS A.beta.40 were
also lowered by 12.1%, but this figure did not reach statistical
significance (p=0.118).
[0158] A complex immunohistochemical analysis of these samples was
performed to define the area of brain tissue showing plaque
pathology. Sections were taken from the cortex at the level of the
caudate and from the cortex at the level of the hippocampus.
Adjacent sections were stained with either an A.beta.40 or
A.beta.42 specific antibody or alternatively with the amyloid stain
Congo Red. Using image analysis software, the area of the section
stained for plaque was expressed as a percentage of the total
section area.
[0159] After fixation, the PFA-immersed half brains were coronally
cut in a brain matrix into 6.times.2 mm thick sections. These 2 mm
sections will be referred to as sections A to F, A being the most
rostral and F the most caudal. Sections A, B & C and D, E &
F were placed in separate embedding cassettes numbered for each
animal. Cassettes were held in PFA until ready for processing and
embedding.
[0160] Embedding was undertaken on a Citadel.TM. 1000 (Shandon)
tissue processor. All tissues received the following processing
regimen:--
70% IMS--1 hr
100% IMS--3.times.1 hr
[0161] 100% ethanol--2 hr 100% isobutyl alcohol; 1.times.2 hr;
1.times.1.5 hr
Histoclear.TM.--2.times.1.5 hr
[0162] Paraffin wax--2.times.2 hr
[0163] On completion of the processing cycle, the wax impregnated
tissue sections were transferred to molten-paraffin wax filled base
moulds and embedded utilising a Histocentre.TM. (Shandon) paraffin
embedding system. Tissue was embedded such that sections A, B &
C went into one mould; D, E & F into a second mould. This was
carried out for all sets of sections ie. each hemisected brain
resulted in two wax blocks of three sections each. Sections were
placed in the moulds such that the caudal surface of each piece
became the future cutting surface. Care was taken to ensure that
each section was pushed well down in the mould so that microtoming
of each would occur in parallel. The perforated processing cassette
was then carefully placed onto each mould which was then topped up
with molten wax. Embedded blocks were then cooled on the
refrigerated plate until they could be removed from the moulds.
Blocks were stored at room temperature until required for
microtoming. Blocks were cut at random and 5 micron sections
floated onto prelabelled gelatine coated slides (Superfrost.TM.,
Erie Scientific Company) slides. Two sections were floated onto
each slide. Wherever possible, consecutive sections were mounted
and slides were numbered consecutively from 1 to 25. Fifty sections
(25 slides) were taken from each block. Slides were dried on a hot
plate and then stored at room temperature until required.
[0164] Immunohistochemistry was undertaken on sets of 30 slides. On
each slide, the top section was labelled with an A.beta.40 antibody
(G30, rabbit polyclonal recognising x-40 .beta.-amyloid), the lower
section with the A.beta.42 antibody, 20G10, monoclonal antibody
recognising x-42 .beta.-amyloid. A minimum of 5 sections per
antibody per block were labelled.
[0165] Labelling was carried out as follows. Following dewaxing
through Histoclear and graded alcohols, sections were immersed in
85% formic acid for 8 minutes and then blocked in 0.3% hydrogen
peroxide for 30 minutes to block endogenous peroxidases. Antibodies
G30 and 20G10 were both applied overnight at 1:1000 dilutions,
sections being left at 4.degree. C. Development of the sections was
with the respective biotinylated anti rabbit and anti-mouse
secondaries. Colour development was accomplished with a
diaminobenzidine tetrahydrochloride staining kit (DAB.TM., Vector
Labs). Sections were briefly counterstained with Mayer's
hematoxylin before being dehydrated, cleared and cover-slipped.
[0166] Sections were left to dry for at least 48 hours before
microscopy. Images were captured on a Leica DMRB.TM. microscope
equipped with digital camera. Images were analysed using Qwin.TM.
software (Leica) and results presented as % of the section area
that was labelled by the A.beta. antibody.
[0167] An analysis of variance was used with treatment, sex and
dosing schedule included in the model as fixed effects. All of the
interactions between the three factors were also included. There
were no significant differences between the two dosing schedules
(once or twice weekly). With this experimental design, firstly we
could assess if there were any significant differences between the
dosing schedules and secondly, as there were no such significant
differences, data from the two dosing schedules could be combined,
thus increasing the power of the experiment by doubling the number
of mice in the analysis.
[0168] In this paradigm, treatment with 2E7 antibody reduced plaque
pathology as measured with an antibody recognising A.beta.42.
Plaque pathology was reduced by 27.1% (p=0.0026) in the cortex at
the level of the hippocampus and 43% (p<0.0001) in the cortex at
the level of the caudate. Plaque pathology was also reduced when
measured with an antibody recognising A.beta.40. Plaque pathology
was reduced by 16.6% (p=0.0421) in the cortex at the level of the
hippocampus and 17.3% (p=0.0342) in the cortex at the level of the
caudate.
[0169] No evidence of microhaemorrhage (as determined by Perls'
Prussian Blue) was observed in any mice from this study treated
with vehicle or 2E7. This method visualises ferric iron (iron is an
essential constituent of the oxygen-carrying haemoglobin found in
red cells) by producing an insoluble blue compound. All levels of
brain from all animals were clear.
Cognition Models
[0170] Following the 4 month dosing of 4 month old TASTPM mice as
described above, these mice were tested in two models of cognition:
the object recognition assay and the fear conditioning assay.
Object Recognition Assay
[0171] The object recognition assay exploits the animals' natural
propensity to explore novel objects and relies on the animals'
ability to recall an object which had been explored previously
(familiar object). Eight month old TASTPM mice have been reported
to demonstrate a deficit in the ability to distinguish between
novel and familiar objects (Howlett et al., 2004) indicating
impaired cognitive performance in these animals. In this study,
however, 8 month-old TASTPM mice treated with vehicle failed to
demonstrate cognitive impairment i.e. they were able to distinguish
between novel and familiar objects. There was therefore no window
to investigate any potential therapeutic effect resulting from
treatment with 2E7.
Fear Conditioning Assay
[0172] The fear conditioning model was designed to test the
animals' ability to correlate a previous painful stimulus with a
contextual or cued signal and recall this when presented with the
same context or tone following Xh delay. In this study 8-month old
TASTPM mice treated with vehicle (once or twice weekly) exhibited a
deficit in contextual differentiation indicative of cognitive
impairment in these animals. This deficit was unaffected by
treatment with 2E7 when administered once of twice weekly
4 Month Dosing of 6 Month Old TASTPM Mice
[0173] This study involved the administration of 2E7 (300 ug i.p.
twice weekly) to TASTPM mice for 4 months, starting at 3 months of
age. Control animals received IgG2A in PBS. As described above,
brains were dissected and hemisected. The right hemisphere was
fixed by immersion in 4% paraformaldehyde and processed for
histology. The left hemisphere was collected into pre-weighed 2 ml
Eppendorf.TM. tubes, frozen on dry ice and stored at -80.degree. C.
for subsequent analysis of amyloid content.
[0174] A preliminary analysis of a single section from each of a
random selection of brain samples (n=6 vehicle, n=7 2E7 treated
group) by IHC was undertaken using the same general protocol as
above. Statistical analysis (Student's t-test) shows that there was
a significant decrease in A.beta.42 plaque load in thalamus (71.9%,
p=0.007) and in thalamus+cortex+hippocampus (54.1%, p=0.022) in
mice dosed with 2E7 but no significant change in A.beta.40.
[0175] For biochemical measurement of brain A.beta.40 and
A.beta.42, samples were processed and measured as above (dilution
factor 1:10,000). A.beta.42 was significantly decreased (p=0.01) by
29.9% in mice dosed with 2E7 (n=12 control, n=16 treated).
A.beta.40 concentrations were also decreased (22.6%) but this
decrease failed to reach statistical significance (p=0.052).
Cloning of Hybridoma Variable Regions
Variable Region Sequences
[0176] Total RNA was extracted from 2E7 hybridoma cells and heavy
and light variable domain cDNA sequences were then generated by
reverse transcription and polymerase chain reaction (RT-PCR). The
forward primer for RT-PCR was a mixture of degenerate primers
specific for murine immunoglobulin gene leader-sequences and the
reverse primer was specific for the antibody constant regions, in
this case murine isotype IgG2a for the heavy chain and murine kappa
for the light chain. Primers were designed according to the
strategy described by Jones and Bendig (Bio/Technology 9:88, 1991).
RT-PCR was carried out in duplicate for both V-region sequences to
enable subsequent verification of the correct V-region sequences.
The V-region products generated by RT-PCR were cloned (Invitrogen
TA Cloning Kit) and sequence data obtained.
TABLE-US-00011 2E7 V.sub.H Amino Acid Sequence (SEQ ID No: 17)
EVKLVESGGGLVQPGGSLKLSCAVSGFTFSDNGMAWVRQAPRKGPE
WIAFISNLAYSIDYADTVTGRFTISRDNAKNTLYLEMSSLRSEDTA
MYYCVSGTWFAYWGQGTLVTVSA 2E7 V.sub.H DNA Sequence (SEQ ID No: 18)
GAGGTGAAGCTGGTGGAGTCTGGGGGAGGCTTAGTGCAGCCTGGAG
GGTCCCTGAAACTCTCCTGTGCAGTCTCTGGATTCACTTTCAGTGA
CAACGGAATGGCGTGGGTTCGACAGGCTCCAAGGAAGGGGCCTGAG
TGGATAGCGTTCATTAGTAATTTGGCATATAGTATCGACTACGCAG
ACACTGTGACGGGCCGATTCACCATCTCTAGAGATAATGCCAAGAA
TACCCTGTACCTGGAAATGAGCAGTCTGAGGTCTGAGGACACGGCC
ATGTACTATTGTGTAAGCGGGACCTGGTTTGCTTACTGGGGCCAAG
GGACTCTGGTCACTGTCTCTGCA 2E7 V.sub.L Amino Acid Sequence (SEQ ID No:
19) DWLTQTPLSLPVSLGDQASISCRVSQSLLHSNGYTYLHWYLQKPGQ
SPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFC SQTRHVPYTFGGGTKLEIK
2E7 V.sub.L DNA Sequence ((SEQ ID No: 20)
GATGTTGTGCTGACCCAAACTCCACTCTCCCTGCCTGTCAGTCTTG
GAGATCAAGCCTCCATCTCTTGCAGAGTTAGTCAGAGCCTTTTACA
CAGTAATGGATACACCTATTTACATTGGTACCTGCAGAAGCCAGGC
CAGTCTCCAAAGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTG
GGGTCCCAGACAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCAC
ACTCAAGATCAGCAGAGTGGAGGCTGAGGATCTGGGAGTTTATTTC
TGCTCTCAAACTAGACATGTTCCGTACACGTTCGGAGGGGGGACCA AGCTGGAAATAAAA
[0177] Complementarity Determining Regions (CDRs) are underlined in
the amino acid sequences.
Cloning and Expression of 2E7 Chimera
[0178] A chimeric 2E7 antibody (2E7c) consisting of the parent
murine V regions grafted on to human IgG1 (Fc mutated (L235A,
G237A)) for the heavy chain or human C kappa regions for the light
chain was generated in order to express recombinant antibody
material that could be used to confirm the correct cloning of
functional murine V regions. DNA encoding 2E7 murine heavy and
light chain V regions and endogenous murine signal sequences was
cloned in frame into the mammalian expression vectors RLD-bshe (for
the heavy chain) and RLN-bshe (for the light chain) already
containing human constant regions (IgG1 Fc mutated (L235A, G237A)
or human C kappa, respectively).
[0179] Elements of RLD-bshe expression vector for heavy chain
expression:
TABLE-US-00012 Base Pairs Description of DNA segment 0-1014
Promoter (SV40/RSV) 1015-2442 Antibody heavy chain 2443-2765 Poly A
2766-3142 BG Promoter 3239-3802 DHFR 3803-4162 Poly A 4163-6322
Total backbone 5077-5937 (complementary Beta lactamase strand)
(position of elements and overall size of vector given above are
for illustration purposes only and will depend upon the size of the
antibody chain insert)
[0180] Elements of RLN-bshe expression vector for light chain
expression:
TABLE-US-00013 Base Pairs Description of DNA segment 0-1014
Promoter (SV40/RSV) 1015-1731 Antibody light chain 1732-2051 Poly A
2388-2764 BG Promoter 2774-3568 Neomycin 3569-3876 Poly A 3877-6063
Total backbone 5077-5937 Beta lactamase (complementary strand)
(position of elements and overall size of vector given above are
for illustration purposes only and will depend upon the size of the
antibody chain insert)
[0181] Clones with correctly cloned V.sub.H and V.sub.L sequences
were identified and plasmids prepared for expression in suspension
culture CHO cells. Expressed 2E7c antibody was purified from cell
culture supernatant by protein A chromatography on a FPLC system,
and then tested for binding to A.beta. by ELISA and SPR using
Biacore.TM. technology. The results indicated that the correct 2E7
mouse V regions were cloned and expressed, resulting in a
functional antibody with similar characteristics to the parent
murine antibody 2E7.
Light Chain Humanisation
[0182] A human acceptor sequence with the Genpept ID CAA51135 (SEQ
ID No:24) and Genbank Accesion No X72467, which had 77% identity on
the amino acid level (including CDRs) was selected as the acceptor
framework. Construct L1 is a graft of the murine CDRs from the 2E7
VL domain into this acceptor framework.
Heavy Chain Humanisation
[0183] Human sequence Genbank accession No M99675 (SEQ ID No:21) an
allele of the VH3-48 gene with 74% identity on the amino acid level
(including CDRs 1 and 2) to the 2E7 mouse variable heavy region was
selected as the human heavy chain acceptor framework together with
the human JH4 minigene. Three humanised variable heavy chain
variants were designed based on the M99675 sequence and JH4. H1 is
a graft of the murine CDRs using the Kabat definition with two
additional framework back mutations at positions 93 and 94. H2 and
H3 were both derived from H1, but incorporated one additional
framework mutation which were different in each construct;
(positions 24 and 48 respectively; see Table 4).
TABLE-US-00014 TABLE 4 Template Residue Construct frameworks
(Kabat#) Human Mouse H1 M99675 93, 94 A and R V and S and JH4
respectively respectively H2 H1 24 A V H3 H1 48 V I
Construction of Humanised Heavy and Light Chain DNA
[0184] Humanised V regions were synthesised de novo by build up of
overlapping oligos and PCR amplification. Restriction sites for
cloning into mammalian expression vectors RLD-bshe and RLN-bshe and
human immunoglobulin signal sequences derived from the chosen human
acceptor frameworks were included. The DNAs encoding the humanised
V regions (H1 (SEQ ID NO:27), H2 (SEQ ID NO:29), H3 (SEQ ID NO:31),
L1 (SEQ ID NO:33)) together with signal sequences and restriction
sites were then cloned in frame into mammalian expression vectors:
H1, H2 and H3 into RLD-bshe to generate DNA encoding three full
length human IgG1 Fc mutated heavy chains each containing mutations
L235A and G237A, full length H1 (SEQ ID NO:35), full length H2 (SEQ
ID NO:37) and full length H3 (SEQ ID NO:39); L1 was cloned in frame
into RLN-bshe containing the DNA encoding human kappa constant
region to generate DNA encoding a full length human kappa light
chain (SEQ ID NO:41).
Representative Examples of Expression of Humanised Heavy and Light
Chain Antibody Combinations
[0185] CHOK1 cells were transiently transfected at small scale with
all combinations of humanised light and heavy chain DNA constructs:
L1+H1, L1+H2, L1+H3 (SEQ ID Nos: 35+41, 37+41, 39+41) in 6-well
plates. CHOK1 cells passaged in DMEM F12, with 5% ultra low IgG
foetal bovine serum and 2 mM glutamine were grown to confluency in
6-well plates. The confluent cells were transfected with a total of
7.5 .mu.g DNA: 30 .mu.g Transfast lipid (Promega) in Optimem
Glutamax medium (Invitrogen). Transfected cells were incubated at
37.degree. C. with 5% CO.sub.2. At 72 hours supernatants were
harvested and assayed for antibody concentration and then tested
for binding to human A.beta. by ELISA. Humanized L1 combined with
the three humanized heavy chains all expressed complete antibody
that bound to human A.beta..
[0186] Humanized antibodies were also expressed in large scale
transient CHOK1 cell transfections using liposomal delivery of DNA
(eg TransFast (Promega)) and expression in culture bottles. For
optimization of expression levels in transient transfections a
heavy to light chain expression vector DNA ratio of 1:6 was used.
Material from transient transfection was purified using ProSepA
columns or FPLC with ProSepA HiTrap columns.
Assessment of 2E7 Humanised Variants H1L1, H2L1 and H3 L1 in
.beta.-Amyloid Binding ELISA
[0187] 2E7 H1L1, H2L1 and H3L1 humanised variants were assessed for
binding to human A.beta. peptide (1-40) biotinylated at the C
terminus. The chimeric 2E7 was used as a reference. Tables 5-7 show
results with various batches of purified material from large scale
transient transfections.
TABLE-US-00015 TABLE 5 EC.sub.50 Standard ELISA MAb (.mu.g/ml)
Error A.beta. binding 2E7c Chimera 0.033 0.00144 H1L1 0.035 0.00142
H2L1 0.048 0.00202 H3L1 0.044 0.00105
TABLE-US-00016 TABLE 6 EC.sub.50 Standard ELISA MAb (.mu.g/ml)
Error A.beta. binding 2E7c Chimera 0.043 0.00183 H1L1 0.051 0.00164
H2L1 0.044 0.00191 H3L1 0.055 0.00094
TABLE-US-00017 TABLE 7 EC.sub.50 Standard ELISA MAb (.mu.g/ml)
Error A.beta. binding 2E7c Chimera 0.044 0.00169 H1L1 0.047 0.00265
H2L1 0.041 0.00174 H3L1 0.040 0.00116
[0188] These results indicated very similar A.beta. binding
profiles for each of the 2E7-derived humanised variants. Comparison
of the EC50 values to the 2E7c showed little loss of A.beta.
binding activity had been incurred through the humanization
process.
Comparison of 2E7 Humanised Variants by Competition ELISA
[0189] 2E7c chimeric and humanised antibodies H1L1, H2L1 and H3L1
were assessed for their ability to inhibit the binding between the
human A.beta. peptide and the parental mouse 2E7 MAb in a
competition ELISA.
[0190] Two types of competition ELISA were established in order to
compare the A.beta. binding activity of the three humanised
variants compared to the 2E7 chimeric antibody.
1) Immobilised .beta.-amyloid; biotinylated human A.beta. peptide
(1-40) was immobilized through Streptavidin on ELISA plates Mouse
2E7 antibody was added at a constant concentration along with a
dilution series of 2E7-derived humanised variant antibodies. Bound
mouse 2E7 MAb was then detected with anti-mouse IgG conjugate.
Table 8 shows results of two assays.
TABLE-US-00018 TABLE 8 Experiment Experiment 1 Standard 2 Standard
Competitor MAb IC.sub.50 (.mu.g/ml) Error IC.sub.50 (.mu.g/ml)
Error 2E7c Chimera 1.31 0.20 1.29 0.13 H1L1 1.62 0.40 1.76 0.21
H2L1 1.28 0.26 1.66 0.28 H3L1 1.53 0.16 1.39 0.23
2).beta.-amyloid in solution; a constant concentration of
.beta.-amyloid was pre-incubated with a dilution series of
humanised 2E7 antibody variants--the mixture including complexed
and free amyloid was added for a short time to wells containing
immobilised mouse 2E7 MAb. The amount of free .beta.-amyloid that
was still available for binding the immobilised parental 2E7 MAb
was then detected. Table 9 shows results of two assays.
TABLE-US-00019 TABLE 9 Experiment Experiment 1 Standard 2 Standard
Competitor MAb IC.sub.50 (.mu.g/ml) Error IC.sub.50 (.mu.g/ml)
Error 2E7c Chimera 0.052 0.006 -- -- H1L1 0.114 0.014 0.140 0.024
H2L1 0.075 0.009 0.119 0.014 H3L1 0.069 0.004 0.115 0.013
[0191] All humanised antibody variants inhibited the binding of
mouse 2E7 MAb to .beta.-amyloid with a very similar profile.
IC.sub.50 values generated for H2L1 and H3L1 variants were
consistently close to that of the 2E7c chimera (where used), which
had the highest inhibitory activity in both assays. However,
variant H1L1 showed a somewhat reduced inhibitory activity in both
assays, indicating a possible slightly lower affinity for
.beta.-amyloid.
SPR Biacore.TM. Analysis of 2E7, 2E7c, H1L1, H2L1, H3L1
[0192] The kinetics parameters of recombinant mouse 2E7 MAb,
chimeric 2E7c and humanized variants H1L1, H2L1 and H3L1 binding to
human beta-amyloid peptide (1-40) and (1-42) were assessed using
Biacore.TM. analysis on a Biacore.TM. 3000. Two different assay
formats were used.
Method A
[0193] (i) Briefly, <20 resonance units of beta-amyloid 1-40
peptide (biotinylated at the C-terminus) were captured on a
streptavidin biosensor chip (as used for Table 10A). The antibodies
were diluted down in HBS-EP buffer and passed over the
streptavidin/beta-amyloid surface at concentrations ranging from
0.001 nM-8 nM (for Table 10A). Two separate runs were carried out;
each run was carried out on a new streptavidin/beta-amyloid
surface. Runs 1 and 2 were essentially the same though there were
some differences in the parameters used; Run 1 was carried out
using a chip surface on which 16 RU's of beta-amyloid were
captured, and antibody concentrations of 0.001 nM-8 nM were used,
an association time of 4 minutes and a dissociation time of 20
minutes were used at a flow rate of 50 .mu.l per minute. For Run 2,
less than 10 RU's of beta-amyloid were captured and antibody
concentrations of 0.003125 nM-8 nM were used. The flow rate and
association times were the same as Run 1, however the dissociation
time was reduced to 15 minutes. (ii) Beta amyloid (1-40) and (1-42)
were amine-coupled on different surfaces of a CM5 biosensor chip to
a level of <20 resonance units (as used for Table 10B). The
antibodies were diluted down in HBS-EP buffer and passed over the
biosensor/beta-amyloid surface at concentrations ranging from 1
nM-64 nM (as used for Table 10B).
Method B
[0194] In the second instance the assay was reversed, in that
antibodies were first captured to a level of 1000-2500 resonance
units on an anti-mouse IgG polyclonal antibody surface (for
recombinant mouse 2E7 MAb) or a protein A surface (for humanized
H2L1) of a CM5 biosensor chip. Freshly prepared beta-amyloid (1-40)
or (1-42) was diluted down in HBS-EP buffer and passed over the
captured-antibody surface at concentrations ranging from 4-500 nM
(Table 10C and 10D).
[0195] In both methods, regeneration was via a pulse of 100 mM
H.sub.3PO.sub.4, and for Table 10A data also followed by a pulse of
50 mM NaOH. The surface was shown to be stable and unaffected by
regeneration. All runs were double referenced against buffer blank
injections. Analysis was carried out using the Biacore.TM. analysis
software BIAevaluation version 4.1.
Results
[0196] Method A(i) was used to rank order the antibodies by
beta-amyloid binding kinetic data. The data obtained is shown in
Table 10A. This shows that the parental 2E7 Mab has a KD of 36.1 pM
for streptavidin-captured beta-amyloid. The chimeric mouse-human
antibody showed a slightly reduced KD of 45.8 pM and the humanised
constructs range from 54 (H2L1) to 93.6 pM (H1L1). In conclusion
this demonstrates that the humanisation procedure had been very
successful and very little affinity had been lost. The additional
backmutations introduced for H2 and H3 had a small but beneficial
effect, although the differences between H2 and H3 constructs are
within the standard deviations for these experiments.
TABLE-US-00020 TABLE 10A Antibody ka kd KD(pm) 2E7 Run 1 1.61e6
6.17e-5 38.3 Run 2 1.69e6 5.72e-5 33.8 Average(SD) 1.65e6 5.97e-5
36.1(3.2) c2E7 Run 1 1.34e6 6.44e-5 48.1 Run 2 1.3e6 5.65e-5 43.5
Average(SD) 1.32e6 6.10e-5 45.8(3.3) H1L1 Run 1 5.60e5 5.32e-5 95.0
Run 2 6.37e5 5.87e-5 92.2 Average(SD) 5.99e5 5.60e-5 93.6(2.0) H2L1
Run 1 9.91e5 5.76e-5 58.1 Run 2 1.1e6 5.49e-5 49.8 Average(SD)
1.05e6 5.63e-5 54.0(5.9) H3L1 Run 1 8.24e5 6.26e-5 76.0 Run 2 8.3e5
4.75e-5 57.2 Average(SD) 8.27e5 5.47e-5 66.6(13.3)
[0197] Method A(ii) was used to confirm that the additional two
amino-acid residues on the C-terminus of beta-amyloid (1-42)
compared to beta-amyloid (1-40) did not significantly alter the
binding properties of 2E7 and H2L1. The data obtained is shown in
Table 10B and did confirm this.
TABLE-US-00021 TABLE 10B Beta- ka kd KD Antibody amyloid
(Ms.sup.-1) (s.sup.-1) (pM) 2E7 1-40 4.05e5 1.28e-4 317 1-42 3.82e5
1.51e-4 394 H2L1 1-40 3.33e5 1.22e-4 366 1-42 3.40e5 1.55e-4
456
[0198] Method B was used to negate avidity effects potentially seen
in the first assay format. Avidity effects, caused by both Fab
domains of a single antibody molecule binding at the same time to
two adjacent beta-amyloid molecules on the biosensor surface (or in
multimeric forms of beta-amyloid), would increase the apparent
affinity of binding. Affinity measurements obtained using Method B
are shown in Table 10C.
TABLE-US-00022 TABLE 10C KD (nM) ka kd With Standard Antibody
(Ms.sup.-1) (s.sup.-1) Deviation n = 3 2E7 2.83e5 .+-. 0.54e5
4.28e-4 .+-. 0.65e-4 1.58 .+-. 0.55 H2L1 1.06e5 .+-. 0.27e5 7.50e-4
.+-. 0.50 7.32 .+-. 1.64
[0199] Evidence that this assay provided true 1:1 binding
affinities was obtained when Fab fragments of H2L1, obtained by
papain digestion, bound streptavidin-captured beta-amyloid (1-40)
by a similar method to Method A(i) with an estimated KD of 2.4
nM.
[0200] Method B was also used to confirm that the additional two
amino-acid residues on the C-terminus of beta-amyloid (1-42)
compared to beta-amyloid (1-40) did not significantly alter the
binding properties of an identical sequence clone to mouse 2E7 MAb,
named 2F11. The data obtained is shown in Table 10D.
TABLE-US-00023 TABLE 10D Beta- ka kd KD Antibody amyloid
(Ms.sup.-1) (s.sup.-1) (nM) 2F11 1-42 2.39e5 2.74e-4 1.14 2F11 1-40
2.99e5 3.92e-4 1.31
[0201] In a study similar to the epitope mapping study on 2E7 using
the Surface Plasmon Resonance assay described above, H2L1 behaved
similarly to 2E7 in binding to the peptide encompassing amino acids
1-12 (A.beta.1, SEQ ID No:15) of the .beta.-amyloid peptide and not
to the peptide encompassing amino acids 2-13 of the .beta.-amyloid
peptide (A.beta.2-13, SEQ ID No:44).
Activity of H2L1 in the I.sup.125 R-Amyloid Efflux Model
[0202] In order to functionally compare the humanised H2L1 with the
parent mouse monoclonal 2E7, both were tested on the same day in
the I.sup.125 .beta.-amyloid efflux model described above.
[0203] Both H2L1 and 2E7 significantly increased counts per minute
(CPM) in blood compared with vehicle control. CPM of radioactivity
in blood was as follows (Vehicle: 1940.+-.166; 2E7: 10065.+-.1386;
H2L1: 10913.+-.1535). Statistics used were ANOVA with post-hoc LSD
test. n=7 vehicle, n=6 2E7, n=6 H2L1, (p<0.001 for each test
compound vs. vehicle).
[0204] This data provides further evidence that the humanised H2L1
antibody has retained the functional properties shown with the
mouse 2E7 molecule.
Investigation of the Pharmacokinetics of H2L1 and 2E7
[0205] The terminal half life of test antibody in mice was
investigated. Test antibody was administered by a 1 h intravenous
infusion to 4 mice to achieve a target dose of 400 ug per mouse.
Serial blood samples were taken from each mouse up to 5 days after
dosing (one mouse from the 2E7 group did not complete the study and
one from the H2L1 group was removed from subsequent analysis
because it became apparent the dose had not been administered
i.v.). Antibody levels were measured using a .beta.-amyloid capture
ELISA.
[0206] Analysis of the data indicates that the humanised antibody
H2L1 has a terminal half life of circa 82 hours in mice (Table 11),
which is comparable to that of the parent mouse monoclonal antibody
2E7 (circa 75 hours).
TABLE-US-00024 TABLE 11 Mean .+-. SD Parameter (n = 3) Cmax (ug/mL)
291 .+-. 43 Tmax (h) # 2.0 (1.1-2.1) CLp (mL/h/kg) 0.9 .+-. 0.1
t1/2 (h) 82 .+-. 4 Vss (mL/kg) 94 .+-. 12 # median and range Cmax
Observed maximum plasma concentration. Tmax Time of the observed
maximum plasma concentration CLp Total plasma clearance;
Dose/AUC.sub.(0-inf). t1/2 Terminal phase half-life was determined
as the ratio of In2/z where z is the terminal phase rate constant;
calculated using unweighted linear regression analysis (after log
transformation) on those concentration-time pairs occurring after
the visually assessed onset of the terminal log-linear phase. Vss
Volume of distribution at steady-state; CLp .times.
MRT.sub.0-inf.
Effect of H2L1 on Peripheral Amyloid Load in Aged Non-Human
Primates
[0207] A study was conducted in aged Cynomolgus monkeys
(approximately 15 years old) to investigate the exposure response
relationship with respect to amyloid/H2L1 complex formation and
clearance and the subsequent effects on CSF and CNS amyloid levels.
Weekly lumbar CSF (taken under ketamine sedation) and blood samples
were collected 3 weeks prior to 1.sup.st dose of H2L1. Immediately
following sampling on week 3, animals received placebo (n=10), 0.1
mg/kg (n=5), 1 mg/kg (n=5) or 10 mg/kg (n=10) H2L1 and then every 2
weeks for 12 weeks. Blood samples for plasma analysis of H2L1 and
total A.beta..sub.42 were taken weekly. CSF samples for
quantification of A.beta..sub.40/42 were collected every 2 weeks.
Following completion of the dosing period, animals were euthanased
for the purpose of brain quantification of beta-amyloid by
biochemical analyses as described above and investigation of
microhaemorrhage. In the lowest dose group (0.1 mg/kg), animals
were euthanased in a staggered fashion to evaluate the potential
time course effect in brain levels as a consequence of termination
of dosing and hence saturation of the plasma amyloid pool.
[0208] This study was approved by the Institutional Animal Care and
Use Committee (IACUC) of MACCINE Pte Ltd, or "Maccine" prior to
start of the experimental phase. The IACUC protocol number was
#08-2006. GSK has performed a site visit of Maccine and has
reviewed their ethical review process and found it acceptable
[0209] Plasma samples were serially diluted 1:10 to 1:50000 and
added to A.beta..sub.40 coated ELISA plates. Standard curves were
created ranging from 0-10 .mu.g/ml H2L1 in diluent. Following an
overnight incubation at 4.degree. C. H2L1 was visualised using
anti-human IgG horseradish peroxidase (Amersham-diluted 1:2000 in
diluent) and tetramethylbenzidene detection system. Following
single and repeat iv bolus administration, plasma levels of H2L1
appeared to increase in a dose dependent fashion. There was no
evidence of severe non-linearities in the pharmacokinetics,
indicating that for the majority of the dosing interval, excess
molar concentrations of H2L1 in the plasma compared with free
amyloid levels were achieved.
[0210] Total A.beta..sub.42 was measured in neat plasma using a
commercially available A.beta. 1-42 ELISA kit (Innogenetics) in
accordance with the manufacturers instructions, with standard
curves ranging from 500-7 pg/ml created in kit diluent. Samples and
standards are incubated overnight at 4.degree. C. before assaying
in duplicate according to kit instructions. It should be noted that
due to the interference of the detection antibody supplied with the
A.beta..sub.42 assay, this kit cannot be used to measure free
A.beta..sub.42 levels but measures the apparent `total`
A.beta..sub.42. There was a dose and concentration dependent
increase in A.beta..sub.42 (with plateau levels of approximately
300, 125 and 25 pg/ml detected following 10, 1 or 0.1 mg/kg H2L1
respectively).
[0211] From the analysis, the increase in the "total
A.beta..sub.42" is likely to be due to the result of a significant
efflux of amyloid from outside the plasma pool, that appeared
dependent upon H2L1 concentrations >1 ug/mL, and did not appear
to be a result of lack of clearance of complex. This was evident by
the elimination rate of the total A.beta..sub.42 as well as the
fluctuation in the total levels over a dosing interval.
[0212] To date only the plasma analysis has been completed and
fully analysed. However preliminary analysis indicates that there
was a trend towards reduction in CSF and increase in the
hippocampal level of `total` A.beta.42 (measured as generally
described above) following treatment with 10 mg/kg H2L1.
[0213] In some brain sections, small areas of microhaemorrhage were
detected as shown by the Perls' Prussian Blue staining method. This
method visualises ferric iron (iron is an essential constituent of
the oxygen-carrying haemoglobin found in red cells) by producing an
insoluble blue compound. However there was no difference in the
incidence between vehicle and drug treated animals.
Analyses on Aged Cynomologus Macaque Monkeys for Beta Amyloid
Plaques in the Brain and Total Beta Amyloid in the Plasma
[0214] Cerebral spinal fluid (CSF) and tissue parameters of human
AD have been displayed in the cynomolgus monkey. The aged
cynomolgus monkey has been shown to have evidence of amyloid
deposition. (Covance, The cynomolgus monkey as a model for
Alzheimer's disease. In: Buse E, Habermann G, Friderichs-Gromoll S,
Kaspereit J, Nowak P and Niggemann K, editors. Poster Presentation
at the 44th Annual Meeting of the Society of Toxicology, New
Orleans, La., 6 to 10 Mar. 2005). The potential for H2L1 to elicit
an inappropriate response (such as encephalitis) in an aged brain
was investigated in old, ca. 20 years, ex-breeding female monkeys.
In addition, safety, treatment-related microhaemorrhage,
neutralization/clearance of test material, hypersensitivity, and
immune complex disease were also investigated following intravenous
administration for 8 weeks in two-weekly intervals. In addition CNS
and blood samples were analysed for levels of
A.beta..sub.40/42.
Study Design
[0215] Groups of 5 (group 1), 9 (group 2) or 10 (group 3) geriatric
female cynomolgus monkeys were given 0 (vehicle), 50 or 100
mg/kg/dosing day H2L1 in vehicle (4 ml/kg) every second week for 8
weeks intravenously by slow bolus administration. The vehicle
consisted of sodium acetate trihydrate 6.81 mg/mL, disodium edetate
dehydrate 0.0186 mg/mL, polysorbate 80 0.2 mg/mL, and L-Arginine
base 10 mg/mL, the pH was 5.5. Dose levels were chosen to
investigate dose levels that were 5 and 10 fold intended clinical
dose levels.
[0216] The following evaluations were performed pre-dose, daily
(clinical signs, body weight, food consumption), week 4 and the
week before necropsy: in-life animal observations, body weight,
body temperature, haematology, clinical chemistry (including
cerebrospinal fluid [CSF] analysis), urinalysis, and cytokine
determination in CSF. Following necropsy, organ weights,
macroscopic observations, and microscopic observations of the
brain, cervical spinal cord and gross lesions were conducted on all
animals. Toxicokinetic evaluation was performed after each
dosing.
Results
[0217] There were no unscheduled deaths, and there were no signs
which indicated an influence of the test item on the general
condition of the animals at the administered doses. The only
remarkable observations in clinical pathology (hematology and serum
chemistry) were concluded to be age- and not test article
related.
[0218] Systemic exposure to H2L1 (as measured by AUC.sub.0-.tau.
and C.sub.max) increased approximately in proportion to dose. For
both dose groups, there was no marked change (.gtoreq.2-fold) in
systemic exposure between the 1st dose and 4th dose sampling
periods.
[0219] There were no signs of inflammatory reactions in the brain
detected by CSF-analysis, and there were no macroscopic or
microscopic findings at necropsy that suggested a test item
influence, specifically no microhaemorrhage or encephalitis.
[0220] This study was conducted in compliance with the Good
Laboratory Practice Regulations as outlined in German Chemical Law,
annex 1 and 2 to .sctn.19a Chemikalien Gesetz, June 2002, the OECD
Principles of Good Laboratory Practice (revised 1997, issued
January 1998) ENV/MC/CHEM (98) 17, the Consensus Document "The
Application of the OECD Principles of GLP to the Organisation and
Management of Multi-Site Studies" ENV/JM/MONO (2002)9. Studies
conducted in compliance with the above regulations and standards
were considered acceptable to US FDA regulatory authorities.
Analysis of Plaque Load in the CNS
[0221] The left brain hemispheres of the vehicle treated
cynomologus macaque monkeys from the above study were analysed by
immunohistochemistry. A coronal section, at the level of the middle
temporal sulcus containing portions of the dentate gyrus and
hippocampus, was processed into wax as described above. For
immunohistochemistry, sections were labelled with a pan-A.beta.
antibody (1 E8, monoclonal antibody raised to A.beta. 13-27), or
with the A.beta.42 antibody, (20G10, monoclonal antibody
recognising A.beta. x-42), and labelling was developed as above. A
visual count of the number of plaques was taken for each section.
Tissue from all five vehicle-treated cynomolgus monkeys showed
evidence of parenchymal A.beta. plaques. There was also evidence of
cerebrovascular labelled A.beta. and intraneuronal A.beta..
Analysis of Beta Amyloid/Antibody Complexes in Plasma
[0222] Biochemical analysis was carried out on plasma samples from
two time points (at the end of weeks 4 and 8 after start of dosing)
from animals dosed with 50 mg/kg (n=9) or 100 mg/kg (n=10) H2L1, or
vehicle dosed controls (n=5). 100 ul duplicate samples were
analysed using the commercially available Innogenetics A.beta. 1-42
ELISA kit, incubated overnight at 4.degree. C. Control samples were
analysed both neat and at 1:10 dilution (using the supplied
diluent), while samples from the dosed animals were tested neat and
at 1:25. Subsequent absorbance values were analysed, with unknown
absorbance values backcalculated to pg/ml values using standard
curves, and then corrected for any assay dilution. Total plasma
levels of A.beta.42 derived from these samples are shown in Table
12 below (figures in pg/ml.+-.SE); all samples from animals treated
with H2L1 contained significantly higher levels of A.beta.42
(p<0.001 by student t-test) than in control groups.
TABLE-US-00025 TABLE 12 Week 4 (pg/ml) Week 8 (pg/ml) Control
(1:10) 104.1 .+-. 30.4 29.8 .+-. 7.9 50 mg/kg (1:25) 830.5 .+-.
79.1 615.8 .+-. 50.2 100 mg/kg (1:25) 1020.5 .+-. 84.4 492.7 .+-.
46.3
[0223] Data reported were obtained from diluted samples. Results
from the neat samples were not used as many data points were either
greater than the top standard, or due to sample volume limitation,
only assayed as a single point.
Production Process
[0224] Expression vectors encoding H2L1 and operatively linked to
amplifiable selection markers such as the DHFR or glutamine
synthetase may be used to transfect or transduce appropriate
parental CHO cell lines (eg CHODG44 or CHOK 1) to produce
engineered cell lines suitable for production of monoclonal
antibody at large scale (for review see Bebbington and Hentschel
DNA Cloning Volume III; A practical approach (edited by Glover D M)
(Oxford IRL press, 1987). In order to increase expression levels
the coding sequence maybe codon optimized in order to avoid
cis-acting sequence motifs and extreme GC contents (high or low).
SEQ. ID Nos:42 and No:43 exemplify such a coding sequence for H2
heavy chain and L1 light chain. Large scale production maybe in
stirred tank bioreactors using animal-derived-component-free
medium, followed by purification. This may comprise clarification
of the harvest, followed by Protein-A affinity chromatography, and
further purification using ion (e.g. cation) exchange and mixed
mode (e.g. ceramic hydroxyapatite) chromatography unit operations.
A virus removal nanofiltration is followed by a final
ultrafiltration/diafiltration step that enables formulation
suitable for the intended route of administration.
Example of Pharmaceutical Formulation
TABLE-US-00026 [0225] Ingredient Quantity (per mL) H2L1 50 mg
Sodium acetate trihydrate 6.81 mg Polysorbate 80 0.20 mg Arginine
base 10.00 mg Sodium chloride 3.00 mg Disodium edetate dihydrate
0.0186 mg Hydrochloric acid qs to give pH 5.5 Water for Injections
To make 1.0 mL Nitrogen To fill headspace
TABLE-US-00027 Amino Acid Sequences of V-regions of Acceptor
Frameworks and Humanised Variants M99675 heavy chain acceptor
framework V region, amino acid sequence (SEQ ID No: 21)
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEW
VSYISSSSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVY YCAR M99675 heavy
chain acceptor framework V region DNA (SEQ ID No: 22)
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGG
GTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCT
ATAGCATGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGG
GTTTCATACATTAGTAGTAGTAGTAGTACCATATACTACGCAGACTC
TGTGAAGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCAC
TGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTAT TACTGTGCGAGAGA
CAA51135 light chain acceptor framework V region amino acid
sequence (SEQ ID No: 24)
DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQ
SPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCM QALQTPWTFGQGTKVEIK
CAA51135 light chain acceptor framework V region DNA (SEQ ID No:
25) GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGG
AGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATA
GTAATGGATACAACTATTTGGATTGGTACCTGCAGAAGCCAGGGCAG
TCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGT
CCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGA
AAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATG
CAAGCTCTACAAACTCCGTGGACGTTCGGCCAAGGGACCAAGGTGGA AATCAAA Humanised
heavy chain V region variant H1, amino acid sequence (SEQ ID No:
26) EVQLVESGGGLVQPGGSLRLSCAASGFTFSDNGMAWVRQAPGKGLEW
VSFISNLAYSIDYADTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVY
YCVSGTWFAYWGQGTLVTVSS Humanised heavy chain V region variant H1 DNA
coding sequence (SEQ ID No: 27)
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGG
GTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTGACA
ACGGAATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGG
GTTTCATTCATTAGTAATTTGGCATATAGTATCGACTACGCAGACAC
TGTGACGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCAC
TGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTAT
TACTGTGTCAGCGGGACCTGGTTTGCTTACTGGGGCCAGGGCACACT AGTCACAGTCTCCTCA
Humanised heavy chain V region variant H2, amino acid sequence (SEQ
ID No: 28) EVQLVESGGGLVQPGGSLRLSCAVSGFTFSDNGMAWVRQAPGKGLEW
VSFISNLAYSIDYADTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVY
YCVSGTWFAYWGQGTLVTVSS Humanised heavy chain V region variant H2 DNA
(SEQ ID No: 29) GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGG
GTCCCTGAGACTCTCCTGTGCAGTCTCTGGATTCACCTTCAGTGACA
ACGGAATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGG
GTTTCATTCATTAGTAATTTGGCATATAGTATCGACTACGCAGACAC
TGTGACGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCAC
TGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTAT
TACTGTGTCAGCGGGACCTGGTTTGCTTACTGGGGCCAGGGCACACT AGTCACAGTCTCCTCA
Humanised heavy chain V region variant H3, amino acid sequence (SEQ
ID No: 30) EVQLVESGGGLVQPGGSLRLSCAASGFTFSDNGMAWVRQAPGKGLEW
ISFISNLAYSIDYADTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVY
YCVSGTWFAYWGQGTLVTVSS Humanised heavy chain V region variant H3 DNA
(SEQ ID No: 31) GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGG
GTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTGACA
ACGGAATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGG
ATCTCATTCATTAGTAATTTGGCATATAGTATCGACTACGCAGACAC
TGTGACGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCAC
TGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTAT
TACTGTGTCAGCGGGACCTGGTTTGCTTACTGGGGCCAGGGCACACT AGTCACAGTCTCCTCA
Humanised light chain V region variant L1 amino acid sequence (SEQ
ID No: 32) DIVMTQSPLSLPVTPGEPASISCRVSQSLLHSNGYTYLHWYLQKPGQ
SPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCS QTRHVPYTFGGGTKVEIK
Humanised light chain V region variant L1 DNA (SEQ ID No: 33)
GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGG
AGAGCCGGCCTCCATCTCCTGCAGAGTTAGTCAGAGCCTTTTACACA
GTAATGGATACACCTATTTACATTGGTACCTGCAGAAGCCAGGGCAG
TCTCCACAGCTCCTGATCTATAAAGTTTCCAACCGATTTTCTGGGGT
CCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGA
AAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCTCT
CAAACTAGACATGTTCCGTACACGTTCGGCGGAGGGACCAAGGTGGA AATCAAA Mature H1
heavy chain amino acid sequence (Fc mutated double mutation bold)
(SEQ ID No: 34) EVQLVESGGGLVQPGGSLRLSCAASGFTFSDNGMAWVRQAPGKGLEW
VSFISNLAYSIDYADTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVY
YCVSGTWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG
CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS
SSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV
HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP
IEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIA
VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC
SVMHEALHNHYTQKSLSLSPGK H1 Full length DNA (SEQ ID No: 35)
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGG
GTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTGACA
ACGGAATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGG
GTTTCATTCATTAGTAATTTGGCATATAGTATCGACTACGCAGACAC
TGTGACGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCAC
TGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTAT
TACTGTGTCAGCGGGACCTGGTTTGCTTACTGGGGCCAGGGCACACT
AGTCACAGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCC
TGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGC
TGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAA
CTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTAC
AGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCC
AGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCC
CAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACA
AAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCGCGGGGGCA
CCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGAT
CTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACG
AAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTG
CATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTA
CCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATG
GCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACA
GGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCC
GTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCAC
GCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGC
TCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGC
TCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCT
CTCCCTGTCTCCGGGTAAA
Mature H2 heavy chain amino acid sequence, (Fc mutated double
mutation bold) (SEQ ID No: 36)
EVQLVESGGGLVQPGGSLRLSCAVSGFTFSDNGMAWVRQAPGKGLEW
ISFISNLAYSIDYADTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVY
YCVSGTWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG
CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS
SSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV
HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP
IEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIA
VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC
SVMHEALHNHYTQKSLSLSPGK H2 Full length DNA (SEQ ID No: 37)
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGG
GTCCCTGAGACTCTCCTGTGCAGTCTCTGGATTCACCTTCAGTGACA
ACGGAATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGG
GTTTCATTCATTAGTAATTTGGCATATAGTATCGACTACGCAGACAC
TGTGACGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCAC
TGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTAT
TACTGTGTCAGCGGGACCTGGTTTGCTTACTGGGGCCAGGGCACACT
AGTCACAGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCC
TGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGC
TGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAA
CTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTAC
AGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCC
AGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCC
CAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACA
AAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCGCGGGGGCA
CCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGAT
CTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACG
AAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTG
CATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTA
CCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATG
GCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACA
GGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCC
GTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCAC
GCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGC
TCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGC
TCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCT CTCCCTGTCTCCGGGTAAA
Mature H3 heavy chain amino acid sequence (Fc mutated double
mutation bold) (SEQ ID No: 38)
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDNGMAWVRQAPGKGLEW
ISFISNLAYSIDYADTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVY
YCVSGTWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG
CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS
SSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV
HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP
IEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIA
VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC
SVMHEALHNHYTQKSLSLSPGK H3 full length DNA (SEQ ID No: 39)
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGG
GTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTGACA
ACGGAATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGG
ATCTCATTCATTAGTAATTTGGCATATAGTATCGACTACGCAGACAC
TGTGACGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCAC
TGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTAT
TACTGTGTCAGCGGGACCTGGTTTGCTTACTGGGGCCAGGGCACACT
AGTCACAGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCC
TGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGC
TGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAA
CTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTAC
AGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCC
AGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCC
CAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACA
AAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCGCGGGGGCA
CCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGAT
CTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACG
AAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTG
CATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTA
CCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATG
GCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACA
GGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCC
GTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCAC
GCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGC
TCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGC
TCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCT CTCCCTGTCTCCGGGTAAA
Mature Light chain amino acid sequence (SEQ ID No: 40)
DIVMTQSPLSLPVTPGEPASISCRVSQSLLHSNGYTYLHWYLQKPGQ
SPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCS
QTRHVPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL
NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSK
ADYEKHKVYACEVTHQGLSSPVTKSFNRGEC L1 Full length DNA (SEQ ID No: 41)
GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGG
AGAGCCGGCCTCCATCTCCTGCAGAGTTAGTCAGAGCCTTTTACACA
GTAATGGATACACCTATTTACATTGGTACCTGCAGAAGCCAGGGCAG
TCTCCACAGCTCCTGATCTATAAAGTTTCCAACCGATTTTCTGGGGT
CCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGA
AAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCTCT
CAAACTAGACATGTTCCGTACACGTTCGGCGGAGGGACCAAGGTGGA
AATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCAT
CTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTG
AATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGACAA
CGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACA
GCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAA
GCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCA
GGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT Optimised H2 heavy
chain DNA (SEQ ID No: 42)
GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTGCAGCCTGGCGG
CAGCCTGAGACTGAGCTGTGCCGTGTCCGGCTTCACCTTCAGCGACA
ACGGCATGGCCTGGGTGAGGCAGGCCCCTGGCAAGGGCCTGGAGTGG
GTGTCCTTCATCAGCAACCTGGCCTACAGCATCGACTACGCCGACAC
CGTGACCGGCAGATTCACCATCAGCCGGGACAACGCCAAGAACAGCC
TGTACCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTAC
TACTGTGTGAGCGGCACCTGGTTCGCCTACTGGGGCCAGGGCACCCT
GGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCC
TGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGC
TGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAA
CAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGC
AGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGC
AGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCC
CAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACA
AGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGGCCGGAGCC
CCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGAT
CAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACG
AGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTG
CACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTA
CCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACG
GCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCT
ATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCA
GGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGG
TGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCC
GTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCAC
CCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGC
TGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGC
TCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCT GAGCCTGTCCCCTGGCAAG
Optimised L1 light chain DNA (SEQ ID No: 43)
GACATCGTGATGACCCAGAGCCCCCTGAGCCTGCCCGTGACCCCTGG
CGAGCCCGCCAGCATCAGCTGTAGAGTGAGCCAGAGCCTGCTGCACA
GCAACGGCTACACCTACCTGCACTGGTATCTGCAGAAGCCTGGCCAG
AGCCCTCAGCTGCTGATCTACAAGGTGTCCAACCGGTTCAGCGGCGT
GCCTGATAGATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGA
AGATCAGCAGAGTGGAGGCCGAGGATGTGGGCGTGTACTACTGCTCC
CAGACCAGACACGTGCCTTACACCTTTGGCGGCGGAACAAAGGTGGA
GATCAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCA
GCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTG
AACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAA
TGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACA
GCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAG
GCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCA
GGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC
Sequence CWU 1
1
4415PRTMouse 1Asp Asn Gly Met Ala1 5 216PRTMouse 2Phe Ile Ser Asn
Leu Ala Tyr Ser Ile Asp Tyr Ala Asp Thr Val Thr1 5 10 15 36PRTMouse
3Gly Thr Trp Phe Ala Tyr1 5 416PRTMouse 4Arg Val Ser Gln Ser Leu
Leu His Ser Asn Gly Tyr Thr Tyr Leu His1 5 10 15 57PRTMouse 5Lys
Val Ser Asn Arg Phe Ser1 5 69PRTMouse 6Ser Gln Thr Arg His Val Pro
Tyr Thr1 5 716PRTArtificial SequenceSynthetic peptide 7Asp Ala Glu
Phe Arg His Asp Ser Gly Tyr Gly Ser Gly Gly Ser Lys1 5 10 15
816PRTArtificial SequenceSynthetic peptide 8Asp Ala Glu Phe Arg His
Asp Ser Gly Gly Ser Gly Ser Gly Ser Lys1 5 10 15 916PRTArtificial
SequenceSynthetic peptide 9Asp Ala Glu Phe Arg His Asp Ser Gly Ser
Gly Gly Ser Gly Gly Lys1 5 10 15 1016PRTArtificial SequenceAmino
acid sequence identified using molecular biology techniques. 10Asp
Ala Glu Phe Arg His Asp Gly Ser Gly Gly Ser Gly Gly Ser Lys1 5 10
15 1116PRTArtificial SequenceAmino acid sequence identified using
molecular biology techniques. 11Asp Ala Glu Phe Arg His Gly Ser Gly
Gly Ser Gly Gly Ser Gly Lys1 5 10 15 1216PRTArtificial
SequenceAmino acid sequence identified using molecular biology
techniques. 12Asp Ala Glu Phe Arg Gly Ser Gly Gly Ser Gly Gly Ser
Gly Ser Lys1 5 10 15 1316PRTArtificial SequenceAmino acid sequence
identified using molecular biology techniques. 13Asp Ala Glu Phe
Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Lys1 5 10 15
1416PRTArtificial SequenceAmino acid sequence identified using
molecular biology techniques. 14Asp Ala Glu Gly Ser Gly Gly Ser Gly
Gly Ser Gly Gly Ser Gly Lys1 5 10 15 1516PRTArtificial
SequenceAmino acid sequence identified using molecular biology
techniques. 15Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val Gly
Ser Gly Lys1 5 10 15 1616PRTArtificial SequenceAmino acid sequence
identified using molecular biology techniques. 16Ser Glu Val Lys
Met Asp Ala Glu Phe Arg His Asp Gly Ser Gly Lys1 5 10 15
17115PRTMouse 17Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln
Pro Gly Gly1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Val Ser Gly Phe
Thr Phe Ser Asp Asn 20 25 30 Gly Met Ala Trp Val Arg Gln Ala Pro
Arg Lys Gly Pro Glu Trp Ile 35 40 45 Ala Phe Ile Ser Asn Leu Ala
Tyr Ser Ile Asp Tyr Ala Asp Thr Val 50 55 60 Thr Gly Arg Phe Thr
Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr65 70 75 80 Leu Glu Met
Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Val
Ser Gly Thr Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 100 105
110 Val Ser Ala 115 18345DNAMouse 18gaggtgaagc tggtggagtc
tgggggaggc ttagtgcagc ctggagggtc cctgaaactc 60tcctgtgcag tctctggatt
cactttcagt gacaacggaa tggcgtgggt tcgacaggct 120ccaaggaagg
ggcctgagtg gatagcgttc attagtaatt tggcatatag tatcgactac
180gcagacactg tgacgggccg attcaccatc tctagagata atgccaagaa
taccctgtac 240ctggaaatga gcagtctgag gtctgaggac acggccatgt
actattgtgt aagcgggacc 300tggtttgctt actggggcca agggactctg
gtcactgtct ctgca 34519112PRTMouse 19Asp Val Val Leu Thr Gln Thr Pro
Leu Ser Leu Pro Val Ser Leu Gly1 5 10 15 Asp Gln Ala Ser Ile Ser
Cys Arg Val Ser Gln Ser Leu Leu His Ser 20 25 30 Asn Gly Tyr Thr
Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys
Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65
70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser
Gln Thr 85 90 95 Arg His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys
Leu Glu Ile Lys 100 105 110 20336DNAMouse 20gatgttgtgc tgacccaaac
tccactctcc ctgcctgtca gtcttggaga tcaagcctcc 60atctcttgca gagttagtca
gagcctttta cacagtaatg gatacaccta tttacattgg 120tacctgcaga
agccaggcca gtctccaaag ctcctgatct acaaagtttc caaccgattt
180tctggggtcc cagacaggtt cagtggcagt ggatcaggga cagatttcac
actcaagatc 240agcagagtgg aggctgagga tctgggagtt tatttctgct
ctcaaactag acatgttccg 300tacacgttcg gaggggggac caagctggaa ataaaa
3362198PRTHuman 21Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val
Gln Pro Gly Gly1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
Phe Thr Phe Ser Ser Tyr 20 25 30 Ser Met Asn Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Tyr Ile Ser Ser Ser
Ser Ser Thr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe
Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr65 70 75 80 Leu Gln
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95
Ala Arg22296DNAHuman 22gaggtgcagc tggtggagtc tgggggaggc ttggtacagc
ctggggggtc cctgagactc 60tcctgtgcag cctctggatt caccttcagt agctatagca
tgaactgggt ccgccaggct 120ccagggaagg ggctggagtg ggtttcatac
attagtagta gtagtagtac catatactac 180gcagactctg tgaagggccg
attcaccatc tccagagaca atgccaagaa ctcactgtat 240ctgcaaatga
acagcctgag agccgaggac acggctgtgt attactgtgc gagaga 2962315PRTHuman
23Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser1 5 10
15 24112PRTHuman 24Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro
Val Thr Pro Gly1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser
Gln Ser Leu Leu His Ser 20 25 30 Asn Gly Tyr Asn Tyr Leu Asp Trp
Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr
Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65 70 75 80 Ser Arg
Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95
Leu Gln Thr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100
105 110 25336DNAHuman 25gatattgtga tgactcagtc tccactctcc ctgcccgtca
cccctggaga gccggcctcc 60atctcctgca ggtctagtca gagcctcctg catagtaatg
gatacaacta tttggattgg 120tacctgcaga agccagggca gtctccacag
ctcctgatct atttgggttc taatcgggcc 180tccggggtcc ctgacaggtt
cagtggcagt ggatcaggca cagattttac actgaaaatc 240agcagagtgg
aggctgagga tgttggggtt tattactgca tgcaagctct acaaactccg
300tggacgttcg gccaagggac caaggtggaa atcaaa 33626115PRTArtificial
SequenceHumanised 26Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val
Gln Pro Gly Gly1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
Phe Thr Phe Ser Asp Asn 20 25 30 Gly Met Ala Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Phe Ile Ser Asn Leu
Ala Tyr Ser Ile Asp Tyr Ala Asp Thr Val 50 55 60 Thr Gly Arg Phe
Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr65 70 75 80 Leu Gln
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95
Val Ser Gly Thr Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 100
105 110 Val Ser Ser 115 27345DNAHuman 27gaggtgcagc tggtggagtc
tgggggaggc ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag cctctggatt
caccttcagt gacaacggaa tggcgtgggt ccgccaggct 120ccagggaagg
ggctggagtg ggtttcattc attagtaatt tggcatatag tatcgactac
180gcagacactg tgacgggccg attcaccatc tccagagaca atgccaagaa
ctcactgtat 240ctgcaaatga acagcctgag agccgaggac acggctgtgt
attactgtgt cagcgggacc 300tggtttgctt actggggcca gggcacacta
gtcacagtct cctca 34528115PRTHuman 28Glu Val Gln Leu Val Glu Ser Gly
Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15 Ser Leu Arg Leu Ser Cys
Ala Val Ser Gly Phe Thr Phe Ser Asp Asn 20 25 30 Gly Met Ala Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Phe
Ile Ser Asn Leu Ala Tyr Ser Ile Asp Tyr Ala Asp Thr Val 50 55 60
Thr Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr65
70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Val Ser Gly Thr Trp Phe Ala Tyr Trp Gly Gln Gly
Thr Leu Val Thr 100 105 110 Val Ser Ser 115 29345DNAHuman
29gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc
60tcctgtgcag tctctggatt caccttcagt gacaacggaa tggcgtgggt ccgccaggct
120ccagggaagg ggctggagtg ggtttcattc attagtaatt tggcatatag
tatcgactac 180gcagacactg tgacgggccg attcaccatc tccagagaca
atgccaagaa ctcactgtat 240ctgcaaatga acagcctgag agccgaggac
acggctgtgt attactgtgt cagcgggacc 300tggtttgctt actggggcca
gggcacacta gtcacagtct cctca 34530115PRTHuman 30Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15 Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Asn 20 25 30 Gly
Met Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 35 40
45 Ser Phe Ile Ser Asn Leu Ala Tyr Ser Ile Asp Tyr Ala Asp Thr Val
50 55 60 Thr Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser
Leu Tyr65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
Val Tyr Tyr Cys 85 90 95 Val Ser Gly Thr Trp Phe Ala Tyr Trp Gly
Gln Gly Thr Leu Val Thr 100 105 110 Val Ser Ser 115 31345DNAHuman
31gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc
60tcctgtgcag cctctggatt caccttcagt gacaacggaa tggcgtgggt ccgccaggct
120ccagggaagg ggctggagtg gatctcattc attagtaatt tggcatatag
tatcgactac 180gcagacactg tgacgggccg attcaccatc tccagagaca
atgccaagaa ctcactgtat 240ctgcaaatga acagcctgag agccgaggac
acggctgtgt attactgtgt cagcgggacc 300tggtttgctt actggggcca
gggcacacta gtcacagtct cctca 34532112PRTHuman 32Asp Ile Val Met Thr
Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly1 5 10 15 Glu Pro Ala
Ser Ile Ser Cys Arg Val Ser Gln Ser Leu Leu His Ser 20 25 30 Asn
Gly Tyr Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40
45 Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
Lys Ile65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
Cys Ser Gln Thr 85 90 95 Arg His Val Pro Tyr Thr Phe Gly Gly Gly
Thr Lys Val Glu Ile Lys 100 105 110 33336DNAHuman 33gatattgtga
tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60atctcctgca
gagttagtca gagcctttta cacagtaatg gatacaccta tttacattgg
120tacctgcaga agccagggca gtctccacag ctcctgatct ataaagtttc
caaccgattt 180tctggggtcc ctgacaggtt cagtggcagt ggatcaggca
cagattttac actgaaaatc 240agcagagtgg aggctgagga tgttggggtt
tattactgct ctcaaactag acatgttccg 300tacacgttcg gcggagggac
caaggtggaa atcaaa 33634445PRTHuman 34Glu Val Gln Leu Val Glu Ser
Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15 Ser Leu Arg Leu Ser
Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Asn 20 25 30 Gly Met Ala
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser
Phe Ile Ser Asn Leu Ala Tyr Ser Ile Asp Tyr Ala Asp Thr Val 50 55
60 Thr Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95 Val Ser Gly Thr Trp Phe Ala Tyr Trp Gly Gln
Gly Thr Leu Val Thr 100 105 110 Val Ser Ser Ala Ser Thr Lys Gly Pro
Ser Val Phe Pro Leu Ala Pro 115 120 125 Ser Ser Lys Ser Thr Ser Gly
Gly Thr Ala Ala Leu Gly Cys Leu Val 130 135 140 Lys Asp Tyr Phe Pro
Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145 150 155 160 Leu Thr
Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 165 170 175
Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 180
185 190 Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
Lys 195 200 205 Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr
His Thr Cys 210 215 220 Pro Pro Cys Pro Ala Pro Glu Leu Ala Gly Ala
Pro Ser Val Phe Leu225 230 235 240 Phe Pro Pro Lys Pro Lys Asp Thr
Leu Met Ile Ser Arg Thr Pro Glu 245 250 255 Val Thr Cys Val Val Val
Asp Val Ser His Glu Asp Pro Glu Val Lys 260 265 270 Phe Asn Trp Tyr
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 275 280 285 Pro Arg
Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 290 295 300
Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305
310 315 320 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
Ser Lys 325 330 335 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
Leu Pro Pro Ser 340 345 350 Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
Leu Thr Cys Leu Val Lys 355 360 365 Gly Phe Tyr Pro Ser Asp Ile Ala
Val Glu Trp Glu Ser Asn Gly Gln 370 375 380 Pro Glu Asn Asn Tyr Lys
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385 390 395 400 Ser Phe Phe
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 405 410 415 Gln
Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 420 425
430 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445
351335DNAHuman 35gaggtgcagc tggtggagtc tgggggaggc ttggtacagc
ctggggggtc cctgagactc 60tcctgtgcag cctctggatt caccttcagt gacaacggaa
tggcgtgggt ccgccaggct 120ccagggaagg ggctggagtg ggtttcattc
attagtaatt tggcatatag tatcgactac 180gcagacactg tgacgggccg
attcaccatc tccagagaca atgccaagaa ctcactgtat 240ctgcaaatga
acagcctgag agccgaggac acggctgtgt attactgtgt cagcgggacc
300tggtttgctt actggggcca gggcacacta gtcacagtct cctcagcctc
caccaagggc 360ccatcggtct tccccctggc accctcctcc aagagcacct
ctgggggcac agcggccctg 420ggctgcctgg tcaaggacta cttccccgaa
ccggtgacgg tgtcgtggaa ctcaggcgcc 480ctgaccagcg gcgtgcacac
cttcccggct gtcctacagt cctcaggact ctactccctc 540agcagcgtgg
tgaccgtgcc ctccagcagc ttgggcaccc agacctacat ctgcaacgtg
600aatcacaagc ccagcaacac caaggtggac aagaaagttg agcccaaatc
ttgtgacaaa 660actcacacat gcccaccgtg cccagcacct gaactcgcgg
gggcaccgtc agtcttcctc 720ttccccccaa aacccaagga caccctcatg
atctcccgga cccctgaggt cacatgcgtg 780gtggtggacg tgagccacga
agaccctgag gtcaagttca actggtacgt ggacggcgtg 840gaggtgcata
atgccaagac aaagccgcgg gaggagcagt acaacagcac gtaccgtgtg
900gtcagcgtcc tcaccgtcct gcaccaggac
tggctgaatg gcaaggagta caagtgcaag 960gtctccaaca aagccctccc
agcccccatc gagaaaacca tctccaaagc caaagggcag 1020ccccgagaac
cacaggtgta caccctgccc ccatcccggg atgagctgac caagaaccag
1080gtcagcctga cctgcctggt caaaggcttc tatcccagcg acatcgccgt
ggagtgggag 1140agcaatgggc agccggagaa caactacaag accacgcctc
ccgtgctgga ctccgacggc 1200tccttcttcc tctacagcaa gctcaccgtg
gacaagagca ggtggcagca ggggaacgtc 1260ttctcatgct ccgtgatgca
tgaggctctg cacaaccact acacgcagaa gagcctctcc 1320ctgtctccgg gtaaa
133536445PRTHuman 36Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val
Gln Pro Gly Gly1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Val Ser Gly
Phe Thr Phe Ser Asp Asn 20 25 30 Gly Met Ala Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Phe Ile Ser Asn Leu
Ala Tyr Ser Ile Asp Tyr Ala Asp Thr Val 50 55 60 Thr Gly Arg Phe
Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr65 70 75 80 Leu Gln
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95
Val Ser Gly Thr Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 100
105 110 Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
Pro 115 120 125 Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly
Cys Leu Val 130 135 140 Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
Trp Asn Ser Gly Ala145 150 155 160 Leu Thr Ser Gly Val His Thr Phe
Pro Ala Val Leu Gln Ser Ser Gly 165 170 175 Leu Tyr Ser Leu Ser Ser
Val Val Thr Val Pro Ser Ser Ser Leu Gly 180 185 190 Thr Gln Thr Tyr
Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys 195 200 205 Val Asp
Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 210 215 220
Pro Pro Cys Pro Ala Pro Glu Leu Ala Gly Ala Pro Ser Val Phe Leu225
230 235 240 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
Pro Glu 245 250 255 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
Pro Glu Val Lys 260 265 270 Phe Asn Trp Tyr Val Asp Gly Val Glu Val
His Asn Ala Lys Thr Lys 275 280 285 Pro Arg Glu Glu Gln Tyr Asn Ser
Thr Tyr Arg Val Val Ser Val Leu 290 295 300 Thr Val Leu His Gln Asp
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305 310 315 320 Val Ser Asn
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 325 330 335 Ala
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 340 345
350 Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
355 360 365 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
Gly Gln 370 375 380 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
Asp Ser Asp Gly385 390 395 400 Ser Phe Phe Leu Tyr Ser Lys Leu Thr
Val Asp Lys Ser Arg Trp Gln 405 410 415 Gln Gly Asn Val Phe Ser Cys
Ser Val Met His Glu Ala Leu His Asn 420 425 430 His Tyr Thr Gln Lys
Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 371335DNAHuman
37gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc
60tcctgtgcag tctctggatt caccttcagt gacaacggaa tggcgtgggt ccgccaggct
120ccagggaagg ggctggagtg ggtttcattc attagtaatt tggcatatag
tatcgactac 180gcagacactg tgacgggccg attcaccatc tccagagaca
atgccaagaa ctcactgtat 240ctgcaaatga acagcctgag agccgaggac
acggctgtgt attactgtgt cagcgggacc 300tggtttgctt actggggcca
gggcacacta gtcacagtct cctcagcctc caccaagggc 360ccatcggtct
tccccctggc accctcctcc aagagcacct ctgggggcac agcggccctg
420ggctgcctgg tcaaggacta cttccccgaa ccggtgacgg tgtcgtggaa
ctcaggcgcc 480ctgaccagcg gcgtgcacac cttcccggct gtcctacagt
cctcaggact ctactccctc 540agcagcgtgg tgaccgtgcc ctccagcagc
ttgggcaccc agacctacat ctgcaacgtg 600aatcacaagc ccagcaacac
caaggtggac aagaaagttg agcccaaatc ttgtgacaaa 660actcacacat
gcccaccgtg cccagcacct gaactcgcgg gggcaccgtc agtcttcctc
720ttccccccaa aacccaagga caccctcatg atctcccgga cccctgaggt
cacatgcgtg 780gtggtggacg tgagccacga agaccctgag gtcaagttca
actggtacgt ggacggcgtg 840gaggtgcata atgccaagac aaagccgcgg
gaggagcagt acaacagcac gtaccgtgtg 900gtcagcgtcc tcaccgtcct
gcaccaggac tggctgaatg gcaaggagta caagtgcaag 960gtctccaaca
aagccctccc agcccccatc gagaaaacca tctccaaagc caaagggcag
1020ccccgagaac cacaggtgta caccctgccc ccatcccggg atgagctgac
caagaaccag 1080gtcagcctga cctgcctggt caaaggcttc tatcccagcg
acatcgccgt ggagtgggag 1140agcaatgggc agccggagaa caactacaag
accacgcctc ccgtgctgga ctccgacggc 1200tccttcttcc tctacagcaa
gctcaccgtg gacaagagca ggtggcagca ggggaacgtc 1260ttctcatgct
ccgtgatgca tgaggctctg cacaaccact acacgcagaa gagcctctcc
1320ctgtctccgg gtaaa 133538445PRTHuman 38Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Asn 20 25 30 Gly Met
Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45
Ser Phe Ile Ser Asn Leu Ala Tyr Ser Ile Asp Tyr Ala Asp Thr Val 50
55 60 Thr Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95 Val Ser Gly Thr Trp Phe Ala Tyr Trp Gly Gln
Gly Thr Leu Val Thr 100 105 110 Val Ser Ser Ala Ser Thr Lys Gly Pro
Ser Val Phe Pro Leu Ala Pro 115 120 125 Ser Ser Lys Ser Thr Ser Gly
Gly Thr Ala Ala Leu Gly Cys Leu Val 130 135 140 Lys Asp Tyr Phe Pro
Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145 150 155 160 Leu Thr
Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 165 170 175
Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 180
185 190 Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
Lys 195 200 205 Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr
His Thr Cys 210 215 220 Pro Pro Cys Pro Ala Pro Glu Leu Ala Gly Ala
Pro Ser Val Phe Leu225 230 235 240 Phe Pro Pro Lys Pro Lys Asp Thr
Leu Met Ile Ser Arg Thr Pro Glu 245 250 255 Val Thr Cys Val Val Val
Asp Val Ser His Glu Asp Pro Glu Val Lys 260 265 270 Phe Asn Trp Tyr
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 275 280 285 Pro Arg
Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 290 295 300
Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305
310 315 320 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
Ser Lys 325 330 335 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
Leu Pro Pro Ser 340 345 350 Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
Leu Thr Cys Leu Val Lys 355 360 365 Gly Phe Tyr Pro Ser Asp Ile Ala
Val Glu Trp Glu Ser Asn Gly Gln 370 375 380 Pro Glu Asn Asn Tyr Lys
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385 390 395 400 Ser Phe Phe
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 405 410 415 Gln
Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 420 425
430 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445
391335DNAHuman 39gaggtgcagc tggtggagtc tgggggaggc ttggtacagc
ctggggggtc cctgagactc 60tcctgtgcag cctctggatt caccttcagt gacaacggaa
tggcgtgggt ccgccaggct 120ccagggaagg ggctggagtg gatctcattc
attagtaatt tggcatatag tatcgactac 180gcagacactg tgacgggccg
attcaccatc tccagagaca atgccaagaa ctcactgtat 240ctgcaaatga
acagcctgag agccgaggac acggctgtgt attactgtgt cagcgggacc
300tggtttgctt actggggcca gggcacacta gtcacagtct cctcagcctc
caccaagggc 360ccatcggtct tccccctggc accctcctcc aagagcacct
ctgggggcac agcggccctg 420ggctgcctgg tcaaggacta cttccccgaa
ccggtgacgg tgtcgtggaa ctcaggcgcc 480ctgaccagcg gcgtgcacac
cttcccggct gtcctacagt cctcaggact ctactccctc 540agcagcgtgg
tgaccgtgcc ctccagcagc ttgggcaccc agacctacat ctgcaacgtg
600aatcacaagc ccagcaacac caaggtggac aagaaagttg agcccaaatc
ttgtgacaaa 660actcacacat gcccaccgtg cccagcacct gaactcgcgg
gggcaccgtc agtcttcctc 720ttccccccaa aacccaagga caccctcatg
atctcccgga cccctgaggt cacatgcgtg 780gtggtggacg tgagccacga
agaccctgag gtcaagttca actggtacgt ggacggcgtg 840gaggtgcata
atgccaagac aaagccgcgg gaggagcagt acaacagcac gtaccgtgtg
900gtcagcgtcc tcaccgtcct gcaccaggac tggctgaatg gcaaggagta
caagtgcaag 960gtctccaaca aagccctccc agcccccatc gagaaaacca
tctccaaagc caaagggcag 1020ccccgagaac cacaggtgta caccctgccc
ccatcccggg atgagctgac caagaaccag 1080gtcagcctga cctgcctggt
caaaggcttc tatcccagcg acatcgccgt ggagtgggag 1140agcaatgggc
agccggagaa caactacaag accacgcctc ccgtgctgga ctccgacggc
1200tccttcttcc tctacagcaa gctcaccgtg gacaagagca ggtggcagca
ggggaacgtc 1260ttctcatgct ccgtgatgca tgaggctctg cacaaccact
acacgcagaa gagcctctcc 1320ctgtctccgg gtaaa 133540219PRTHuman 40Asp
Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly1 5 10
15 Glu Pro Ala Ser Ile Ser Cys Arg Val Ser Gln Ser Leu Leu His Ser
20 25 30 Asn Gly Tyr Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly
Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe
Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr
Asp Phe Thr Leu Lys Ile65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val
Gly Val Tyr Tyr Cys Ser Gln Thr 85 90 95 Arg His Val Pro Tyr Thr
Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala
Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu
Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln145
150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys
Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys
Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr
His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg
Gly Glu Cys 210 215 41657DNAHuman 41gatattgtga tgactcagtc
tccactctcc ctgcccgtca cccctggaga gccggcctcc 60atctcctgca gagttagtca
gagcctttta cacagtaatg gatacaccta tttacattgg 120tacctgcaga
agccagggca gtctccacag ctcctgatct ataaagtttc caaccgattt
180tctggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac
actgaaaatc 240agcagagtgg aggctgagga tgttggggtt tattactgct
ctcaaactag acatgttccg 300tacacgttcg gcggagggac caaggtggaa
atcaaacgta cggtggctgc accatctgtc 360ttcatcttcc cgccatctga
tgagcagttg aaatctggaa ctgcctctgt tgtgtgcctg 420ctgaataact
tctatcccag agaggccaaa gtacagtgga aggtggacaa cgccctccaa
480tcgggtaact cccaggagag tgtcacagag caggacagca aggacagcac
ctacagcctc 540agcagcaccc tgacgctgag caaagcagac tacgagaaac
acaaagtcta cgcctgcgaa 600gtcacccatc agggcctgag ctcgcccgtc
acaaagagct tcaacagggg agagtgt 657421335DNAHuman 42gaggtgcagc
tggtggagtc tggcggcgga ctggtgcagc ctggcggcag cctgagactg 60agctgtgccg
tgtccggctt caccttcagc gacaacggca tggcctgggt gaggcaggcc
120cctggcaagg gcctggagtg ggtgtccttc atcagcaacc tggcctacag
catcgactac 180gccgacaccg tgaccggcag attcaccatc agccgggaca
acgccaagaa cagcctgtac 240ctgcagatga acagcctgag agccgaggac
accgccgtgt actactgtgt gagcggcacc 300tggttcgcct actggggcca
gggcaccctg gtgaccgtgt ccagcgccag caccaagggc 360cccagcgtgt
tccccctggc ccccagcagc aagagcacca gcggcggcac agccgccctg
420ggctgcctgg tgaaggacta cttccccgaa ccggtgaccg tgtcctggaa
cagcggagcc 480ctgaccagcg gcgtgcacac cttccccgcc gtgctgcaga
gcagcggcct gtacagcctg 540agcagcgtgg tgaccgtgcc cagcagcagc
ctgggcaccc agacctacat ctgtaacgtg 600aaccacaagc ccagcaacac
caaggtggac aagaaggtgg agcccaagag ctgtgacaag 660acccacacct
gccccccctg ccctgccccc gagctggccg gagcccccag cgtgttcctg
720ttccccccca agcctaagga caccctgatg atcagcagaa cccccgaggt
gacctgtgtg 780gtggtggatg tgagccacga ggaccctgag gtgaagttca
actggtacgt ggacggcgtg 840gaggtgcaca atgccaagac caagcccagg
gaggagcagt acaacagcac ctaccgggtg 900gtgtccgtgc tgaccgtgct
gcaccaggat tggctgaacg gcaaggagta caagtgtaag 960gtgtccaaca
aggccctgcc tgcccctatc gagaaaacca tcagcaaggc caagggccag
1020cccagagagc cccaggtgta caccctgccc cctagcagag atgagctgac
caagaaccag 1080gtgtccctga cctgcctggt gaagggcttc taccccagcg
acatcgccgt ggagtgggag 1140agcaacggcc agcccgagaa caactacaag
accacccccc ctgtgctgga cagcgatggc 1200agcttcttcc tgtacagcaa
gctgaccgtg gacaagagca gatggcagca gggcaacgtg 1260ttcagctgct
ccgtgatgca cgaggccctg cacaatcact acacccagaa gagcctgagc
1320ctgtcccctg gcaag 133543657DNAHuman 43gacatcgtga tgacccagag
ccccctgagc ctgcccgtga cccctggcga gcccgccagc 60atcagctgta gagtgagcca
gagcctgctg cacagcaacg gctacaccta cctgcactgg 120tatctgcaga
agcctggcca gagccctcag ctgctgatct acaaggtgtc caaccggttc
180agcggcgtgc ctgatagatt cagcggcagc ggctccggca ccgacttcac
cctgaagatc 240agcagagtgg aggccgagga tgtgggcgtg tactactgct
cccagaccag acacgtgcct 300tacacctttg gcggcggaac aaaggtggag
atcaagcgta cggtggccgc ccccagcgtg 360ttcatcttcc cccccagcga
tgagcagctg aagagcggca ccgccagcgt ggtgtgtctg 420ctgaacaact
tctacccccg ggaggccaag gtgcagtgga aggtggacaa tgccctgcag
480agcggcaaca gccaggagag cgtgaccgag caggacagca aggactccac
ctacagcctg 540agcagcaccc tgaccctgag caaggccgac tacgagaagc
acaaggtgta cgcctgtgag 600gtgacccacc agggcctgtc cagccccgtg
accaagagct tcaaccgggg cgagtgc 6574416PRTArtificial SequenceAmino
acid sequence identified using molecular biology techniques. 44Ala
Glu Phe Arg His Asp Ser Gly Tyr Glu Val His Gly Ser Gly Lys1 5 10
15
* * * * *